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MUC13 Modulated Nanomechanical and Biophysical Responses in Pancreatic
Cancer Cells
Abstract
Pancreatic adenocarcinoma is one of the deadliest forms of cancer. Even with recent advances in
diagnostic tools, chemotherapeutic regimens, and biomarkers for earlier detection, it still has dismal
survival rates. Part of the reason for this is the inherent difficulty in detecting and treating this disease.
Recent findings suggest that the altered expression of mucins, including MUC13, may be useful molecular
signatures for early disease diagnosis, chemotherapy response and predicting patient survival. MUC13, a
recently identified transmembrane glycoprotein, is normally associated with forming a protective barrier
on epithelial tissues. However, its overexpression/aberrant subcellular localization has been associated
with cancer, disease aggressiveness, poorer patient prognosis and drug resistance via alterations of
multiple oncogenic signaling pathways. The main objective of this study is to investigate if MUC13
expression influences nanomechanical and biophysical characteristics of pancreatic cancer cells that
might contribute to aggressive nature of this disease. To achieve this goal, we performed innovative
nanoindentation analyses using atomic force microscopy in conjunction with standard biochemical
assays. To combat this malignant disease, multiple approaches have been considered over the years.
Recently, a unique biophysical method of cancer detection has been explored in other cancers, whereby
an atomic force microscope (AFM) is used to measure the differences in rigidity and adhesion between
normal and cancerous cells. AFMs work by using a thin metallic cantilever with a sharp probe which is
brought into contact with a sample. Due to the interactions between the probe and the sample, various
data can be extracted. AFMs have been used for decades to acquire high resolution, three-dimensional
images of a sample, however it is also possible to acquire other types of data. For cancer research,
biophysical data can help to differentiate between cancerous cells and their healthy counterparts. Current
evidence suggests that normal cells have a greater rigidity than their cancerous counterparts in most
malignancies, however literature dealing with pancreatic cancer is limited. In this report, a comprehensive
overview of various pancreatic cell lines (both cancerous and non-cancerous) was physically investigated.
We noted that there was a significant trend in the reduction of biophysical characteristics associated with
differentiation status - namely, poorly differentiated pancreatic cancer cells (MIA PaCa-2, AsPC-1 and
Panc-1) have significantly lower rigidity values as compared to moderately differentiated (BxPC-3), well
differentiated (HPAF-II) and normal pancreatic epithelia (HPNE). A positive correlation was seen between
the adhesion data and aggregation assays - notably, less aggregation was seen in cancer cells as
compared to HPNE cells, and
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ABSTRACT
Pancreatic adenocarcinoma is one of the deadliest forms of cancer. Even with
recent advances in diagnostic tools, chemotherapeutic regimens, and biomarkers for
earlier detection, it still has dismal survival rates. Part of the reason for this is the inherent
difficulty in detecting and treating this disease. Recent findings suggest that the altered
expression of mucins, including MUC13, may be useful molecular signatures for early
disease diagnosis, chemotherapy response and predicting patient survival. MUC13, a
recently identified transmembrane glycoprotein, is normally associated with forming a
protective barrier on epithelial tissues. However, its overexpression/aberrant subcellular
localization has been associated with cancer, disease aggressiveness, poorer patient
prognosis and drug resistance via alterations of multiple oncogenic signaling pathways.
The main objective of this study is to investigate if MUC13 expression influences
nanomechanical and biophysical characteristics of pancreatic cancer cells that might
contribute to aggressive nature of this disease. To achieve this goal, we performed
innovative nanoindentation analyses using atomic force microscopy in conjunction with
standard biochemical assays.
To combat this malignant disease, multiple approaches have been considered over
the years. Recently, a unique biophysical method of cancer detection has been explored
in other cancers, whereby an atomic force microscope (AFM) is used to measure the
differences in rigidity and adhesion between normal and cancerous cells. AFMs work by
using a thin metallic cantilever with a sharp probe which is brought into contact with a
sample. Due to the interactions between the probe and the sample, various data can be
extracted. AFMs have been used for decades to acquire high resolution, threedimensional images of a sample, however it is also possible to acquire other types of
data. For cancer research, biophysical data can help to differentiate between cancerous
cells and their healthy counterparts. Current evidence suggests that normal cells have a
greater rigidity than their cancerous counterparts in most malignancies, however
literature dealing with pancreatic cancer is limited.
In this report, a comprehensive overview of various pancreatic cell lines (both
cancerous and non-cancerous) was physically investigated. We noted that there was a
significant trend in the reduction of biophysical characteristics associated with
differentiation status - namely, poorly differentiated pancreatic cancer cells (MIA PaCa2, AsPC-1 and Panc-1) have significantly lower rigidity values as compared to
moderately differentiated (BxPC-3), well differentiated (HPAF-II) and normal pancreatic
epithelia (HPNE). A positive correlation was seen between the adhesion data and
aggregation assays - notably, less aggregation was seen in cancer cells as compared to
HPNE cells, and most these cell lines also showed significantly lower membrane
adhesiveness overall.
The effect of various chemotherapeutics or altered protein expression has not
been extensively investigated in this disease state. To address this concern, we
investigated the biophysical effect of several chemotherapeutic compounds on pancreatic
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cancer cells with varied levels of differentiation. Of note, the poorly differentiated cells
were shown to have the greatest modulus increase, while moderate and well
differentiated cells had only minimal increases. Curcumin was shown to have the greatest
biophysical increase of the drugs tested.
Although there is considerable research on the biochemical effects of various
mucins, including MUC13, in cancer, there is currently no data detailing the biophysical
effects of MUC13 in pancreatic cancer. We for the first time have shown that modulation
of MUC13 directly impacts the physical properties of pancreatic cancer cells.
Specifically, overexpression in a Panc-1 transfected model significantly lowered the cell's
modulus, which agrees with the literature consensus that aggressive cells are softer than
their normal counterparts. Knockdown of MUC13 in HPAF-II cells showed the opposite
effect, with a significant increase in both cellular rigidity and adhesion. Once again, the
effects on membrane adhesion were confirmed with in vitro aggregation assays, and a
positive correlation was noted.
In conclusion, we have for the first time shown a comprehensive biophysical
panel of various pancreatic cells and noted differences in their characteristics based on
differentiation status, as well as how these cells were affected by chemotherapeutic
treatment and modulation of MUC13. Given this method of biophysical analysis,
clinicians may be able to measure the effects of various chemotherapeutics more rapidly
than with conventional histological tests, or possibly have earlier diagnostic information
given changes in tissue properties.
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CHAPTER 1.

INTRODUCTION AND LITERATURE SEARCH
Introduction

Cancer is, in its most basic form, an uncontrolled growth of cells within the
human body. These cells have undergone various genetic alterations that separate them
from normal control processes that prevent this type of abnormal growth. These cellular
growths, known as tumors, exhibit multiple hallmarks seen in all varieties of cancer.1–4
x
x
x
x
x
x
x
x
x
x
x

Growth and division in the absence of normal physiological signals
Continuous and irregular growth even with regulatory cessation signals
Avoidance of apoptosis (programmed cell death)
Limitless replication potential
Promotion of angiogenesis (formation of new blood vessels)
Ability to invade into distant tissue site and form metastases
Promoting inflammation
Evading immune responses
Genetic instability and mutations
Deregulated cellular metabolism
A heterogeneous microenvironment that promotes abnormal growth

Figure 1-1 gives a visual summary of these hallmarks. Tumors that possess all
these properties are considered malignant and present a considerable health risk. As of
2016, cancer ranked the second highest cause of death in the United States, just short of
cardiovascular diseases, accounting for 21.9% of all recorded deaths according to a recent
CDC study.5
Although prognosis of this disease state depends on many factors, one important
factor is the tissue of origin. Even though a metastatic disease is always more difficult to
treat and tends to have a lower survival rate, due to advances in either chemotherapy or
surgical techniques survival rates have generally improved for certain cancers, such as
lung, prostate, colorectal, and breast malignancies.6 Although there are still a large
number of cases for these disease states, their overall survival has trended upwards in
recent years. One cancer however remains dismally poor in terms of survival, with recent
survival statistics indicating a less than 10% five-year survival rate: pancreatic cancer.7
Pancreatic Cancer
Pancreatic cancer (PanCa) is an uncontrolled growth of cells originating in the
pancreas, a small, retroperitoneal gland between the stomach and the spine. This organ
has two major functions in the body, acting in an exocrine and an endocrine-based
method and is principally involved in both macronutrient digestion (e.g., carbohydrates,
lipids and proteins) and maintaining blood sugar levels.8 PanCa is divided into two major
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Figure 1-1.

Summary of the major hallmarks of cancer.

Data Sources
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867.
doi:10.1038/nature01322.
Fouad YA, Aanei C. Revisiting the hallmarks of cancer. Am J Cancer Res.
2017;7(5):1016-1036. https://www.ncbi.nlm.nih.gov/pubmed/28560055
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013.
Hlatky L, Hahnfeldt P. Beyond the Cancer Cell: Progression-Level Determinants
Highlight the Multiscale Nature of Carcinogenesis Risk. Cancer Res. 2014;74(3):659664. doi:10.1158/0008-5472.CAN-13-2508.
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types based on the cell of origin – exocrine or neuroendocrine. At least 85% of all
pancreatic malignancies are exocrine – of these, the most common form is pancreatic
ductal adenocarcinoma (PDAC). Endocrine tumors are less common, only accounting for
approximately 5% of all cases.9 When comparing exocrine cancers to neuroendocrine, a
clear difference can be seen in survival rates: exocrine has far lower five-year survival
rates, ranging from 14% (Stage 1A) to only 1% (Stage 4) as compared to neuroendocrine
(61% at Stage 1A to 16% at Stage 4).9 Overall, PanCa remains one of the deadliest forms
of cancer in western countries and is projected to become the second leading cause of
cancer-related death in the United States by 2030.10
According to the American Cancer Society, there will be an estimated 56,770 new
PanCa cases in 2019, with an estimated 45,750 deaths. Currently, there is a 5-year
survival rate of less than 10% for PDAC.7 This poor survival rate is partly due to an
inferior therapeutic response and difficulty in early detection of the disease. Before 2000,
the 5-year survival for PDAC was consistently below 10%; recent advances in detection
methods and therapeutic regiments have begun to improve the condition associated with
this deadly disease.11 Survival rates are typically recorded, as shown in SEER records,
into either localized, regional, or distant cancers - in this fashion, 5-year survival range
from 37.4% at the local stage down to only 2.9% with distant/metastatic cancers.12
In terms of a cure, the only option is a surgical resection as a component of
treatment sequencing, however at least 80% of patients are deemed inoperable once
diagnosed.13 Specifically, only around 15% of patients are found to have a surgically
resectable disease at the time of diagnosis (stages 1 or 2), 35% have a locally advanced
cancer (stage 3), and nearly 50% have metastatic cancer (stage 4). 14 Even for those who
undergo surgery, recurrence is very common.15 In addition, pancreatomy is a complex
surgery associated with significant morbidity and has a high risk of procedure related
complications. Unfortunately, PDAC is a challenging disease to diagnose and detect for
various reasons. Common symptoms of the disease are nonspecific, and include
abdominal pain, weight loss, asthenia, anorexia, irregular stools or urine, and sometimes
jaundice.16 Furthermore, these symptoms are typically only seen with disease progression
- in the early stages of PDAC, symptoms may be milder or not present. In addition, these
signs can be mistaken for other illnesses, such as pancreatitis or an ulcer.9,17
Several serum biomarkers currently exist to measure for PDAC - carbohydrate
antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) - however, they do not have
high sensitivity for PDAC.15 Because of this, it is significantly more difficult for
pathologists to properly diagnose early stage PDAC, and why when diagnosis is
confirmed it is typically already an advanced stage disease. This diagnostic discrepancy
indicates a need for further research into potential biomarkers that can be used for earlier
detection and diagnosis of PDAC.
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Mucins and MUC13
As mentioned previously, there are no definitive biomarkers for PDAC. Although
several are currently in use, including CA19-9 and CEA, they are not considered
sensitive enough to properly detect PDAC. Recently, several promising biomarkers have
been investigated for this disease state, including MUC13, a transmembrane mucin
protein known to be aberrantly expressed in cancers, including PDAC.18–20
Under normal physiological conditions, the mucin family of proteins comprise a
significant component of mucosal surfaces lining various body cavities - especially the
GI tract. They are important in protecting these cavities from pathogens, proteases, and
help to prevent dehydration.21 Mucins contain PTS domains, rich in prolines, threonines
and serines.22 Another common element seen with mucins is extensive O-glycosylation,
which plays a role in this protein's barrier function.23 They are found in one of two
subdivisions, either secreted or transmembrane. Transmembrane mucins (including
MUC13) have only one membrane spanning region that generates its protective effect
through its highly glycosylated structure. These proteins form rod-like structures that
extend far above the cell surface - depending on the specific protein it can extend several
hundred nanometers.22 Recent evidence suggests that mucins act as "sensors" to the
surrounding environment, and under normal circumstances they can trigger pathways
such as membrane repair and maintenance.21
Mucins have been found to be overexpressed in various cancers, including lung24,
ovarian,18 breast,25 and oral cancers26 - however there is evidence that they play a
considerably larger role in gastrointestinal cancers. In response to various stressors, there
is a loss of the normal polarity seen with transmembrane mucins (normally only located
on the apical borders), leading to a repositioning of mucins across the entire epithelial
surface, allowing them to act on proteins not normally in their immediate vicinity,
including various receptor tyrosine kinases.22 In cancerous cells, mucins have been
implicated in acting as a protective outer barrier which can impact drug uptake and
immune surveillance, cell-cell adhesion (partly through its effects on E-cadherin and
beta-catenin), proliferation, apoptosis, and metastasis, while intracellular domains can
activate pathways involved in differentiation.21,27
PDAC has been associated MUC13, a small transmembrane mucin consisting of
only 511 amino acids.27 This protein is normally expressed at low levels in the large
intestine, trachea, kidney, small intestine and gastric epithelium28, although it has been
seen to be aberrantly expressed in a variety of epithelial carcinomas.24,29,30 However,
MUC13 has also been shown in a recent study by Khan et al to be expressed in 100% of
pancreatic intraepithelial neoplasia (PanIN) lesions, and almost 95% of pancreatic ductal
adenocarcinoma (PDAC, the most common form of PanCa). By contrast, this same study
showed only minimal expression in tumor adjacent tissue and virtually no expression in
normal pancreatic tissue31, supporting the notion that MUC13 has a strong role in the
pathology of PDAC and can be a promising diagnostic marker. Figure 1-2 highlights the
major structural components of mucins and Figure 1-3 details MUC13.27,32,33
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Figure 1-2.

Structural overview of transmembrane and secreted mucins.

Data sources
Andrianifahanana M, Moniaux N, Batra SK. Regulation of mucin expression:
Mechanistic aspects and implications for cancer and inflammatory diseases. Biochim
Biophys Acta - Rev Cancer. 2006;1765(2):189-222. doi:10.1016/j.bbcan.2006.01.002.
Rachagani S, Torres MP, Moniaux N, Batra SK. Current status of mucins in the diagnosis
and therapy of cancer. Biofactors. 35(6):509-527. doi:10.1002/biof.64.
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Figure 1-3.

Structural overview of MUC13 protein.

Data sources
Andrianifahanana M, Moniaux N, Batra SK. Regulation of mucin expression:
Mechanistic aspects and implications for cancer and inflammatory diseases. Biochim
Biophys Acta - Rev Cancer. 2006;1765(2):189-222. doi:10.1016/j.bbcan.2006.01.002.
Maher DM, Gupta BK, Nagata S, Jaggi M, Chauhan SC. Mucin 13: structure, function,
and potential roles in cancer pathogenesis. Mol Cancer Res. 2011;9(5):531-537.
doi:10.1158/1541-7786.MCR-10-0443.
Rachagani S, Torres MP, Moniaux N, Batra SK. Current status of mucins in the diagnosis
and therapy of cancer. Biofactors. 35(6):509-527. doi:10.1002/biof.64.
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In PDAC, the overexpression of MUC13 was shown to enhance tumorigenic
features such as proliferation, motility, invasion and in vivo tumor growth. The
suppression of MUC13 was found to have the opposite effects.20 Overall, MUC13
expression correlates with the expression and activation of various oncogenic proteins
including HER2, PAK1, ERK, AKT and metastasin (S100A4), as well as a reduction in
p53.34 These effects show that MUC13 expression is strongly correlated with disease
progression in PDAC.
Various biochemical assays can be used to elucidate the specific effects of
MUC13's effect on cancer cells. In a more general sense, biochemical assays are still a
very common method to delineate the function of various proteins, nucleic acids, or other
small molecules in cancers or other diseases. In recent years, however, there has been an
increasing interest in other methods of measuring cancer cell aggressiveness through
different means. One of the most interesting premises involves measuring the biophysical
properties of cancer cells to determine how they respond to various stimuli, or in more
clinically relevant terms, to see how biophysical data could be used in diagnostic
screening or therapeutic monitoring. Over the past few decades, a new methodology has
emerged that allows for biophysical characterization of live cells. This is based on the
evolution of the relatively recent field of atomic force microscopy. In order to understand
the effects of these modulations, it will be important to understand how these physical
readings will be acquired. Although there are multiple methods to acquire biophysical
data in living cells, this project will specifically focus on the use of atomic force
microscopy and provide a comprehensive overview of its workings and how mechanical
data is acquired.
What Is Atomic Force Microscopy?
Atomic force microscopy (AFM) is a type of scanning probe microscopy (SPM)
which can obtain high-resolution topography of a sample via interactions between the
sample and a sharp probe. These images are obtained using raster scanning, where the
pixels of an image are acquired row by row. With AFM imaging, the attractive and
repulsive forces between the probe tip and sample surface are used to generate the
signal.35 The AFM was developed in 1986 by Binnig et al, building upon previous
scanning tunneling microscope technology developed earlier in the decade. They showed
the potential of this machine in generating images with a lateral resolution of around 30Å
and vertical resolution of less than 1Å.36
There has been a general increase in research interest involving AFMs, especially
with a focus on cancer. A recent PubMed search has shown (as outlined in Figure 1-4) an
increasing number of articles over the past few years using the search terms "atomic force
microscopy" and "atomic force microscopy and cancer" - as of the end of 2019, there are
38950 and 1873 articles in each field, respectively.
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Figure 1-4. PubMed articles listing "atomic force microscopy" and "atomic force
microscopy and cancer" since 2000.
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Typically, very sharp probes (with diameters under 10nm) are used for highresolution imaging on flexible metallic cantilevers. The cantilever is attached to a
piezoelectric stand which moves the probe in the z-axis. A common method of detecting
signal changes involves measuring changes in the reflection of a laser beam that is aimed
onto the back of the cantilever and then reflected onto a photodetector. Based on
deflections in the cantilever, there is a resultant change in the position of the reflected
laser beam - this change is used to generate a voltage signal which can be converted into
an image.37 A general overview of this process is summarized in Figure 1-5.
AFM Imaging Modes: Contact
Several different modes of imaging samples using an AFM have been developed
since the first experiments in the late 1980s. The first imaging method developed on an
AFM was known as contact mode, whereby the probe is brought into direct contact with
the surface and is held at a constant deflection. In this case, changes in the z-axis are used
to generate topographical data. However, since the probe is constantly on the surface, it is
important to control the applied force, as this mode can lead to damage for both the
sample and the probe tip. Any damage to the probe tip can lead to imaging artifacts and
potentially dull the tip, in turn reducing the maximum possible resolution. There is also a
high probability for lateral artifacts which can further lead to image and sample
issues.38,39
Non-Contact
Shortly after contact mode was developed, non-contact mode was introduced.
Here the tip is held several nanometers above the surface of the sample as it is scanned.
Attractive van der Waals forces deflect the cantilever and help to generate the image.
Since these forces are weak, the probe usually must be oscillated - changes in either
amplitude, phase, or frequency of the oscillation can give data on the sample itself.
Recently, this mode has shown potential in revealing intra-molecular resolution,
visualizing individual bonds within molecules.40,41
Tapping
More recently, tapping mode was implemented, where the cantilever oscillated
close to its resonant frequency. This frequency changes when the tip is closer to the
sample surface, and changes are typically seen in the oscillation amplitude. Tapping
mode greatly reduces the lateral forces applied to the sample and is therefore the
preferred imaging technique for biological and other soft or delicate samples.42,43
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Figure 1-5.
generation.

Graphical summary of key AFM components and force curve

10

PeakForce Tapping and ScanAsyst
Over the past few years, a unique variation of tapping mode has been developed
by Bruker known as PeakForce Tapping (PFT). Unlike standard tapping mode however,
PFT generates oscillations at a frequency below the resonant point of the cantilever. This
helps overcome some of the dynamic issues usually seen in a resonant system. Using this
technique, the AFM probe can indent a sample and acquire multiple force curves at
different points, and using real time analysis, multiple types of physical data can be
analyzed at the same time. In addition, unique software algorithms were implemented
allowing for tight control of the applied force during the imaging process, ensuring that a
constant force is always applied even at very high scan rates.44,45
Recently, Schillers et al demonstrated that AFMs can, using PFT, acquire highresolution images able to visualize microvilli on the surface of living cells, structures that
are typically 1-2 microns in length and up to 100nm in diameter. This was accomplished
by keeping a mild interaction force with the surface of the cell of around 100pN, a force
low enough so that the individual microvilli would not be disrupted.46
ScanAsyst, an imaging mode also designed by Bruker, uses PFT in conjunction
with various correction algorithms to provide high quality imaging on a sample surface
by automatically adjusting various imaging parameters in real time. This allows for
automation of a process also called PeakForce Quantitative Nanomechanical Mapping
(PF-QNM). Using this process, an image is generated, and for every point of contact, a
force curve is generated and analyzed. These imaging systems are capable of operating
efficiently in fluids, making them ideal for biological samples.47,48
AFMs and Force Data Collection
The primary use of an AFM is to provide high-resolution, three-dimensional
topographical mapping of a sample. Many other uses have been explored: electrical
measurements49,50, thermal analysis51,52, nanolithography53,54, nanomanipulation55,56, and
probe functionalization for various interaction studies45,57,58 are just a handful of the
various applications of AFM technology.
In addition to being able to collect high-resolution images, the AFM can also
collect highly sensitive force measurements on a variety of samples. This is partly due to
the cantilever itself, which is typically made of silicon or silicon nitride, allowing for
forces in the pico-Newton range to be observed.59 Unlike imaging, where the probe is
simply scanned over the surface of the sample, in force spectroscopy the probe is moved
directly towards the sample until it contacts, presses down to a particular setpoint, then
retracts. In this action, several types of mechanical data can be extracted from the sample:
once in contact, the probe will indent the sample with a specific force. This will lead to a
certain depth of indentation, which can potentially yield information on a sample's elastic
modulus or viscoelasticity.35 One of the properties this study will focus on is the Young's
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modulus, representing the rigidity or stiffness of a material. This property is defined by
Equation 1-1:
ൌ

σ

(Eq. 1-1)

ε

Where E is the Young's modulus, σ represents stress and ε represents strain. This
value refers to the force applied to an object and its resultant deformation. Put simply, for
a constant force, the more a sample deforms, the lower its Young's modulus is (i.e., it is
more flexible). Conversely, for the same applied force, a sample with a higher Young's
modulus will have a lower deformation and is consequently more rigid.
As the probe is retracted from the surface, the sample may adhere to the probe for
a time. This is especially noticeable on softer samples, such as cell membranes. It is also
of importance in samples measured in ambient conditions in air, as meniscus forces will
play a significant role and need to be considered. Once the retraction generates enough
force to separate the sample from the probe, this adhesion force is measured. The
adhesive force with the sample is calculated at the point where the probe is fully
separated from the sample.60 A schematic overview of force data collection on the AFM
is outlined in Figure 1-6.
Force Curve Components and Analysis
One of the most important concepts in AFM data analysis is proper force curve
interpretation. Figure 1-7 depicts a representative force curve taken using our lab's
recently acquired Bruker BioScope Resolve. The X-axis represents the distance from the
surface, and the Y-axis represents the cantilever deflection if uncalibrated, or the force
applied if properly calibrated. Here, we can see the basic actions of the probe - normally,
there is a small dip in the blue line (the "approach" line) - this represents an attractive van
der Waals force when the tip is within a small (~1-5nm) distance from the surface. At the
trough of this dip is where the probe makes contact and begins to deflect upwards - with
proper calibration, this deflection read as a quantifiable force value. Since the force curve
shown in Figure 4 was conducted in fluid, the effects of this attractive force were
reduced. This is more commonly seen when using the probe to analyze samples in air.
The probe will continue pressing down until a pre-determined setpoint (either deflection
distance or force applied) is reached. At this point, it is also possible to determine the
amount of deflection in the sample.61,62
Using these data in conjunction with knowledge about the probe's geometry and
physical parameters it is possible to determine the rigidity (Young's modulus) of a
sample. Next, the probe will begin to retract from the surface. Even in air, there will be
some adhesion to the surface depending on the properties of the sample itself or due to
water meniscus formation.60 In either case, there will tend to be a difference in the shapes
of the blue (approach) and red (retract) curves. Specifically, the red curve tends to go
further down than the blue, showing that a specific force is required to detach the probe
from the sample surface.
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Figure 1-6.

Schematic overview of AFM-based force analysis.

(A) Imaging is conducted using ScanAsyst at lower forces to prevent damage to the cell.
(B) For force analysis, a higher force is used to generate considerable deformation in the
cell membrane. The probe presses down into the cell until the target force is met. (C)
After reaching the target force, the probe is retracted from the surface. Depending on the
sample, it is possible that a portion can adhere to the tip as it retracts from the surface.
(D) As the tip continues to retract from the surface, eventually the force becomes strong
enough to overcome the adhesion between the sample and the probe – this point can be
used to determine the adhesive force between these two objects.

Figure 1-7. Representative force curve generated using Bruker BioScope Resolve
on a clean sample in fluid.
Note the lack of attractive van der Waals interaction on the approach curve - this is partly
due to the probe being immersed in a fluid environment.
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Force Mapping
In addition to the process described above for force curve generation, AFMs can
be used to generate force maps over a defined area to create a pixel map of various
physical parameters. For example, a cell or group of cells can be selected, and a series of
indentations and retractions is conducted over the surface to create a force map. When
analyzed in appropriate software, this map allows one to visualize the intensity of various
properties visually - for instance, if measuring the modulus of a cell, brighter regions
would indicate more rigid regions, while darker areas would indicate softer ones. These
maps can then be quantified to determine the physical properties of the cell overall or at
various regions (e.g., nuclear, cytoplasmic, or peripheral).
Probe Calibration Methods
To properly conduct force analyses, it is important to calibrate the probe being
used. Two properties are needed to properly convert the photodetector signal into a
quantifiable force value: the deflection sensitivity (nm/V) and spring constant (N/m) of
the cantilever. The first value can be determined by generating a force curve on a hard,
clean surface. This will show how much the tip deflects and its relation to the laser
deflection (i.e., the conversion between change in volts on the photodetector to the
distance in nm the cantilever deflects). At the contact region, this relation will be linear
on a hard surface, simplifying the calculations. To calculate the spring constant, several
methods exist - however for probes generally used with biological samples the thermal
tune method is employed.35 The thermal tuning method is based on the equipartition
theorem, in an effort to link the spring constant of the probe to its thermal motion. Put
simply, this theorem states that molecules in thermal equilibrium have the same average
energy over all energetically accessible degrees of freedom within a given system.
During measurement, air molecules will collide with the cantilever and generate
miniscule vibrations. These are measured and then converted into a frequency domain
using Fourier transforms to generate a Power Spectral Density (PSD). Integrating the area
under this peak indicates the power associated with the resonant peak. Unlike other
methods of probe calibration, thermal tune is typically more rapid, and can provide
comparable accuracy to other methods. Although other calibration methods (e.g., the
added mass method) have the potential to be more accurate, they are much more time
consuming and demanding processes. This method is ideal for probes with lower spring
constants (typically below 1N/m).63,64
Atomic Force Microscopy and Biological Samples
Early results with scanning probe microscopes - specifically scanning tunneling
microscopes - in the 1980s proved that this imaging system could be used with soft,
biological samples.65 Such early experiments did run into several issues with image
quality and reproducibility however. By contrast, the AFM, which does not require
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conductive materials for imaging, enabled more efficient imaging on biological
samples.66 AFMs, unlike electron microscopes, can work in a fluid environment and do
not require a vacuum, so they are ideally suited for working with biological samples.
More specifically, it is not possible to visualize living samples using conventional
electron microscopes - particularly scanning electron microscopes (SEM) - due to the
high vacuum in the imaging chamber. Because of this, it is necessary to coat such
samples in a thin layer of a metal such as gold to properly image biological samples67 this requires that cells are fixed with various drying reagents, which can impact their
native morphology.68
If compared to conventional microscopes, there are certain advantages and
disadvantages of AFM imaging. For instance - AFMs can image without the need for any
pretreatments, generate high-resolution, three-dimensional data, and is capable of
generating such images in physiological conditions. More importantly, because of the
interaction between the cantilever and the sample, additional data can be acquired, such
as force spectroscopy.45 This being said, there are some potential caveats with AFM
imaging - conventional imaging is not always fast enough to capture events such as
biological or chemical reactions, which can occur within a fraction of a second. Recent
fast scanning techniques have been produced to address this concern, and as evident in
one recent study demonstrating a technique which was able to show real-time
visualizations of CRISPR-Cas9 reactions.69 Also, due to the mechanism of imaging, only
surface features of a cell can be imaged or analyzed - no data on the cell's interior can be
directly assessed.39
The primary concern for imaging biological materials, particularly living cells, is
how soft the material is compared to conventional materials previously examined using
AFMs. Initial contact mode imaging quickly proved that AFM probes can safely image
cells without rupturing membranes70,71 - however, it was also determined that contact
mode can still inflict damage to a cell due to friction forces, potentially deforming the
membrane enough to show underlying structures If scanning parameters are not properly
calibrated, these forces could even be high enough to rupture the membrane or even
detach the cell from the surface of the plate.39
It was later found out that this contact mode imaging system could deform the
membrane by nearly a full micrometer; if AFM probes pressed this far into a sample
image resolution would be drastically affected. By contrast, tapping mode applied to cell
imaging virtually removes the concerns associated with friction forces and significant
membrane deformation.39 In both imaging modes, adjusting the force to the pico-Newton
range can yield much smoother images, and gives more information on the structure and
complexes seen on the membrane itself.46,72
Cancer Cells and Mechanical Properties
Multiple recent studies have shown that cancer cells, particularly invasive ones,
have a reduced modulus compared to their normal, noncancerous counterparts. In
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addition, factors that further enhance aggressive phenotypes have been associated with a
reduction in cancer cell rigidity. This is partly thought to be due to changes in the
cytoskeletons of cancerous cells compared to their healthy counterparts. To date, the
current literature consensus is that cancerous cells tend to be softer than their normal
counterparts.43,73–77
Given the unique physical characteristics of cancer cells, it is possible to identify
cancerous cells in tissue slides given their altered physical properties. In one study by
Lekka et al, various cancer cell lines were analyzed with respect to normal cells (e.g.,
normal PZHPV-7 compared to cancerous PC-3, DU145 and LNCaP prostate cell lines).
They noted that the cancerous cells had a reduced modulus compared to the normal cells.
Next, patient tissue samples were taken and analyzed at different regions, comparing the
modulus of normal and cancerous tissue. again, it was determined that cancerous cells
had a lower overall modulus compared to normal cells, even at the tissue level.78
Further investigations into the relation between cell stiffness and invasive potential was
investigated by Swaminathan et al. In this study, they determined that softer cancer cells
had a greater invasive and migratory potential, and various treatments that increased
stiffness led to a reduction in invasiveness. This gave credence to an inverse relationship
between cell stiffness and migration and invasion.79
Over the past three decades, AFMs have emerged as a powerful tool for nanoscale characterization, especially for biological samples. With proper force control, it is
now possible to acquire consistent, high-resolution data on living cells and other
biological samples under a variety of conditions. These data can even be overlaid with
fluorescent data to correlate biochemical, morphological, and even physical data with
various alterations (whether pharmacological, genetic, etc). Furthermore, there is some
thought that various phenotypes can be assessed physically, such as differentiation status
or EMT. which can give an insight as to how a cell changes mechanically due to these
processes. One recent example of how cells can be measured for changes in EMT status
was investigated by Cascione et al. In this study, they treated hepatocellular carcinoma
cells with TGF-β, a known promoter of EMT. They found that after treatment, the cells
had significantly lower modulus values as compared to untreated cells. This implied, with
the altered cytoskeletal structures seen with confocal imaging, that the cells had an
increased invasive potential.80
Pancreatic Cancer Cells and Biophysical Analysis
Due to various changes in cellular structure, the current consensus in literature is
that cancer cells tend to be softer than their normal counterparts.76,81,82 AFM force
analysis has been extensively used to highlight the differences in cancer cells, as well as
their biophysical reactions to various alterations such as genetic alterations or
pharmacologic treatment. However, data on PDAC listed in the literature is somewhat
limited, and has sometimes been counterintuitive to the consensus - one notable example
of this was a recent study by Nguyen et al, where they showed that an increased stiffness
was associated with enhanced metastatic potential in PDAC cells.83 Several recent studies
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have shown that the treatment of cancer cells with TGF-β induces EMT and when
analyzed by AFM, these cells are shown to be softer.80,84 However, a recent study that
was conducted using PanCa associated fibroblast cells indicated an increased modulus
with treatment.85 This seems to indicate that the effects of EMT induction are cell
specific.
At the tissue level, additional studies have been conducted and have shown
unique effects in PanCa. In a recent study by Rice et al, cancerous tissue was shown to be
significantly more rigid than healthy tissue (PanIN more so than healthy, and PDAC
more so than PanIN). This was an assessment of the tissue as a whole – when
investigating individual cells, they simulated this increased rigidity by growing cells on
surfaces with increasing rigidity – on more rigid surfaces, PanCa cells were shown to
have increased EMT markers and drug resistance.86 Another recent study has shown a
similar effect at the tissue level – cancerous tissue was again found to be significantly
more rigid than non-cancerous.87 One possible explanation for this was demonstrated in
research by Robinson et al using a three-dimensional ECM model – they showed that
with an increasing number of cells implanted in the model, the overall rigidity of the
structure increased, which is thought to be partly due to matrix remodeling or thickening
of collagen fibers within the tissue.88 Interestingly, a recent study by Zhao et al further
strengthened this notion by showing that PDAC tissues taken from experiments in KPC
mice were significantly softer after PTX treatment.89 This is of note as these studies seem
to contradict the results discussed previously where cancerous tissues in other disease
states were softer than their normal counterparts, although this could simply indicate a
tissue-specific response.
Furthermore, recent studies have shown that an upregulation of EMT markers
(such as vimentin) are associated with a softer cell, while increased levels of E-cadherin,
indicating a less metastatic phenotype, are associated with an increased rigidity.79 This
seems to indicate that the EMT process affects cancer cells in a biophysical manner.
PDAC cells have been analyzed for adhesive properties using AFM studies as
well. One notable example of this was indicated in work published by Cao et al detailing
the interactions between cancer cells and human endothelial cells. When α5 integrin, an
adhesion marker associated with endothelial cells, was blocked, it led to a decrease in the
adhesive interactions between cancer cells and HUVEC cells. The authors stipulated that
the interaction between α5 integrin and neuropilin-2 on the surface of cancer cells was
responsible for the initial stages of extravasation and metastasis.90
As mentioned previously, there is a somewhat limited amount of data regarding
the biophysical responses in PDAC cells in comparison to other cancers. In addition,
there is significantly less data showing how these cells respond to either
chemotherapeutic treatment or genetic alterations. More specifically, it is unclear how
MUC13 can affect PDAC cells physically.
In this manuscript, I sought to quantify the biophysical properties of a panel of
pancreatic cells and their responses to chemotherapeutic treatment and MUC13
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modulation. To this end, we have generated a protocol designed to measure the
biophysical properties of living cells in vitro. This procedure was then used to assess a
comprehensive panel of pancreatic cells, both normal and cancerous to create a baseline
across various differentiation stages. These cancerous cells were then subjected to various
chemotherapeutic treatments to determine if differences in their biophysical responses
could be determined. Lastly, a set of MUC13 modulated cells was used to determine if
altered expression of this protein could lead to changes in the biophysical properties of
these pancreatic cancer cells. Overall, we hypothesize that the use of biophysical
properties will allow for a quantitative method of determining whether various alterations
(pharmacologic or genetic) can be used to assess either therapeutic efficacy or enhanced
oncogenic potential.
To address this hypothesis, we first had to generate a biophysical analysis
protocol that could be used to collect the data in this report. This protocol was then used
to delineate the biophysical properties of normal and cancerous pancreatic cells and see if
any trends could be formed.
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CHAPTER 2. DISCRIMINATION OF NORMAL AND CANCEROUS
PANCREATIC CELL LINE BIOPHYSICAL PROPERTIES AND THEIR
ASSOCIATION WITH DIFFERENTIATION STATUS
Introduction
Although PDAC is not the most common type of cancer, with nearly 57,000 cases
anticipated diagnoses for 2019, it is one of the deadliest types of cancer. Of the newly
diagnosed cases, nearly 46,000 deaths are estimated for the year. PDAC also accounts for
one of the lowest survival rates among cancers, with an estimated 9% 5-year survival
rate.7 Even with recent advances in diagnostic and therapeutic options, the rates of this
cancer incidence and mortality have not changed significantly in the past several decades.
PDAC is commonly diagnosed at a later, more advanced stage as mentioned
previously. Diagnosis is typically confirmed with a biopsy, whereby a small section of
the pancreas (either normal or cancerous) is extracted for microscopic examination.
Pathologists can then stain the tissues and examine them to better understand the disease
state. One factor that is typically examined at this point is differentiation status.
Differentiation Status
In biology, differentiation refers to the ability of cells to gain specialized
functions through various phenotypic changes. It is related to the morphological or
functional resemblance between cancer cells and normal cells from the same tissue of
origin. Differentiation is closely related to tumor grading in PDAC; specifically, the more
well differentiated a tumor is, the lower its grade, meaning it tends to be less metastatic
and more slow growing. In addition, more well differentiated tumors more closely
resemble native, noncancerous tissue of the same organ. This indicates an inverse
correlation between differentiation and proliferative capacity in malignant cells.91 Higher
grade tumors are usually more poorly differentiated, meaning they do not resemble their
normal tissue counterparts. In addition, they usually grow more quickly and indicate a
poorer prognosis, as this type of tumor is more likely to metastasize.92
Differentiation is normally considered a one direction process, however in cancer
it is known that cells can dedifferentiate. This process is commonly used in pathology
and histology as a prognostic marker to indicate tumor aggressiveness. There is some
question as to how strongly tumor cell differentiation overlaps with epithelial to
mesenchymal transition (EMT), a process whereby tumor cells transform from an
epithelial shape to a more firoblastoid-shaped cell with increased motility and
invasiveness. Conceptually speaking, the pathological term of differentiation seems to be
strongly related to EMT progression, even if biological examples are difficult to prove.
Multiple studies have shown the impact of EMT in various cancers93,94, with multiple
studies also emphasizing its importance in PDAC.95–99 Perhaps most interesting is a
recent study by Aiello et al, that suggests a direct correlation between EMT and
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differentiation status, implying that more poorly differentiated PDAC tumors undergo a
more thorough EMT process as compared to more well-differentiated ones.96
From a pathological standpoint, differentiation status refers to the morphological
state of the cancer cells. It is determined using tissue gathered from a biopsy and
analyzed by pathologists to discriminate cancerous tissue from surrounding normal
tissue. Generally speaking, the more well-differentiated a tumor cell is, the more strongly
it resembles its tissue of origin and is typically well organized. More poorly differentiated
tumors lose their epithelial properties and may take on mesenchymal characteristics,
indicative of EMT. This suggests that more poorly differentiated cancer is associated
with a more aggressive phenotype. More poorly differentiated tumors are associated with
a poorer prognosis.92 As suggested by previous research, differentiation status is closely
related to the extent of epithelial to mesenchymal transition (EMT) a cell has
undergone.96
Epithelial to Mesenchymal Transition
Epithelial to mesenchymal transition (EMT) is a process through which epithelial
cells lose their adhesive properties and take on a fibroblast-like, mesenchymal
morphology with increased motility. Although it is a normal process associated with
embryogenesis, tissue development, wound healing and stem cell behavior, it is also
strongly implicated in fibrosis and cancer metastasis. Specifically, it is thought to play a
role via altered gene expression; genes involved in the epithelial state (e.g., E-cadherin)
are repressed by of EMT-associated transcription factors, including SNAIL, TWIST, and
ZEB. Multiple studies have shown that there is a direct correlation between E-cadherin,
EMT markers, and tumor grade in PDAC; specifically, the lower E-cadherin is, the
higher the EMT markers and tumor grade, indicating a poorer the prognosis.96,98
When the EMT process is initiated, specialized cell-cell adherens junctions are
broken down. During this process, epithelial cadherin (E-cadherin) is cleaved and
degraded. This degradation, which can be caused by TGFβ, means that β-catenin is freed
from its association with the cadherins and can then move into the nucleus to act as a
transcription factor. These catenin molecules are typically stabilized by processes such as
WNT signaling, which inhibits glycogen synthase kinase-3β to prevent β-catenin
degradation.96,100
EMT is of interest from a clinical standpoint as it can indicate the level of
metastatic potential that a cancer has. In fact, there is a high degree of correlation
between the pathologic categorization of differentiation and the degree of EMT activation
- in tumors with a more thorough activation of the pathway, cells are typically seen to be
in a more poorly differentiated state, indicating a poorer prognosis. By contrast, more
well-differentiated cells tend to have a reduced level of expressed EMT factors.96
Given the disparate characteristics of differentiation status and EMT on different
stages of cancer, we ran biophysical analyses on a panel of pancreatic cell lines ranging
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from normal epithelial cells, primary tumor, and metastatic lesion derived cell lines. The
cancer cells used in this study were derived from tumors with known differentiation
status. We hypothesized that the more poorly differentiated cells, which are known to be
more aggressive, should have the lowest overall rigidity and membrane adhesion. We
further hypothesized that cells with the lowest measured membrane adhesion would have
a lowered ability to aggregate in vitro.
Overview of Cell Lines
An immortalized human pancreatic epithelial cell line (HPNE) was used as a
reference for normal pancreatic tissue. This cell line, acquired from ATCC, had been
immortalized using a retroviral transduction (pBABEpuro) containing the human
telomerase (hTERT) gene. These cells were made positive for telomerase and failed to
senesce.101
HPAF-II is a well-differentiated cell line obtained from ascites of a 44-year old
male patient with pancreatic adenocarcinoma with metastases to the liver, diaphragm and
lymph nodes. These cells were shown to have a very high expression of VEGF.102 As
shown by results from our lab, these cells express a very high level of MUC13.20
BxPC-3 is a moderately differentiated cell line derived from a 61-year old female
adenocarcinoma from the body of the pancreas. This cell line was acquired from the
primary tumor, and no signs of metastasis were seen upon time of collection. (These cells
lack a kRAS mutation, common to most pancreatic cancers – and thus it may not be
representative of most PDAC). These cells also have some of the highest expression of
COX-2 of a large panel of PDAC cells as shown by Deer et al.102 Results from our lab
indicate a minimal presence of MUC13 in this cell line.31
MIA PaCa-2 was collected from the primary tumor of a 65-year old male patient
with pancreatic adenocarcinoma, and was found to be poorly differentiated.102 Results
published from our lab also indicate that this cell line is MUC13-null.20
AsPC-1 is a poorly differentiated cell line derived from a 62-year old woman with
pancreatic adenocarcinoma of the head and metastases to several organs. These cells
were acquired from an ascitic culture and were found to produce considerable mucin and
carcinoembryonic antigen.102,103 The mucin levels were confirmed in our lab, showing
moderate levels, although not quite as high as seen with HPAF-II.31
Panc-1 is a poorly differentiated cell line acquired from a 56-year old male with
adenocarcinoma of the head that invaded the duodenal wall.102 Like MIA PaCa-2, Panc-1
was found in previous work from our lab to have little to no MUC13 expression.20 Table
2-1 gives a summary of the characteristics of these pancreatic cancer cells.
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Table 2-1.

Characteristics of pancreatic cancer cells used in this study.

Cell line

Differentiation status

Cell type

MUC13 expression

HPAF-II

Well

Metastatic (ascites)

High

BxPC-3

Well-moderate

Primary tumor

Minimal

MIA PaCa-2

Poor

Primary tumor

None

AsPC-1

Poor

Metastatic (ascites)

Moderate

Panc-1

Poor

Primary tumor

Low-none
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Methods
Cell Culture
Cell lines (HPNE, HPAF-II, BxPC-3, MIA PaCa-2, AsPC-1, Panc-1) were
purchased from the American Type Culture Collection (ATCC, Manassas, VA,
USA) and were maintained at 37°C/5% CO2 in growth medium with 10% FBS
(DMEM, Cat. No. 11965092; RPMI-1640, Cat. No. 11875-093; DMEM/Ham's
F12, Cat. No. 11320033, Gibco). HPNE, MIA PaCa-2, and Panc-1 cells were
grown in DMEM media; BxPC-3 and AsPC-1 cells were grown in RPMI; HPAFII cells were grown in DMEM/F-12 media. Cells were grown in T-75 flasks until
at least 70% confluent. Next, media was aspirated under a flow hood and
trypsinized at 37oC until cells were detached. The cells were then centrifuged at
1000 rpm for 5 min, counted, and seeded as needed for the various experiments
discussed below.1
Live Cell AFM Data Analysis
Cells (HPNE, HPAF-II, BxPC-3, MIA PaCa-2, AsPC-1, and Panc-1) were seeded
in 60 mm dishes (2*106 cells per dish, 5mL media per dish) and attached overnight. Cells
were grown in a 37oC incubator as mentioned previously until they reached 75%
confluency. Before imaging, the cells were gently washed with PBS three times and fresh
media was added. The dish was then promptly taken to the AFM (BioScope Resolve,
Bruker) and placed on a heated stage (set to 37oC) and equilibrated for 15 minutes. Using
custom-generated probes with an estimated tip diameter of approximately 130nm46,
designed specifically for live cell applications (PFQNM-LC probes, Bruker), the
deflection sensitivity was calculated via thermal tune in fluid. This calibration only
required one step as each probe had a pre-calibrated spring constant, simplifying the
calibration process. For nanoindentation, a force curve was first generated on the center
of a cell to confirm contact and to select proper settings for the scan. A force volume scan
was then conducted using the ScanAsyst imaging mode using the following settings:
128*128 resolution, 512 samples per ramp, 15Hz ramp rate, 400pN force trigger and
4μm ramp size. This was done to generate a force map over a small group of cells. After
collecting multiple sets of data, the nanomechanical properties (elastic modulus, or
stiffness, and adhesion) were analyzed. Methods of analysis are described in detail in the
"Explanation of Settings for Force Map Analysis" section of this chapter. All force data
analysis was conducted using NanoScope Analysis software (Bruker).104
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Explanation of Settings for Force Map Analysis
Resolution
This resolution (128x128) was chosen to break down the resultant images of cells
into a force map of 16,384 individual force curves. These curves were converted into a
heat map, and the intensity of color corresponds with the intensity of the physical
parameter being measured (i.e., for modulus maps, brighter points indicate areas with
greater rigidity). Representative images of HPNE cells for reference can be seen in
Figure 2-1. These images were then analyzed using NanoScope Analysis software. In the
modulus and adhesion maps, brighter regions correspond to higher values (e.g., more
rigid or adhesive) while darker regions indicate reduced values.
Samples per ramp
This value indicates the resolution of the individual force curve (i.e., the number
of data points used to make each curve) - for these experiments the default value of 512
was kept.
Ramp rate
Although these experiments could have been conducted at slower speeds, it was
decided to use a higher ramp rate to expedite the experiments. If conducted at 1Hz (i.e.,
one ramp per second), each scan would have taken approximately five hours to complete,
given the resolution used in this study. At 15Hz, they only take approximately 20
minutes. This decision was made in order to conduct multiple scans on a single plate.
Moreover, it was necessary to increase the scanning rate to capture as much data as
possible within a three-hour time window to ensure the cells were not aberrantly affected
by a change in the atmosphere. Although it was potentially possible to scan at even
higher rates, preliminary investigations indicated that this increased the hydrodynamic
forces applied to the cells, and significantly reduced the resolution of force imaging. This
was in conjunction with finding out the importance of making sure the vacuum seal was
proper on the plates placed on the AFM stage; if air gaps were present underneath the cell
dish, it could lead to feedback oscillations in the probe during scanning, creating artifacts
that impacted image quality. Furthermore, higher ramp rates were associated with a
higher risk of damaging or detaching cells from the surface of the plate. Therefore, 15Hz
was chosen to minimize scanning time while also preventing unnecessary damage to the
cell from these additional forces. A slower speed would have further reduced this risk,
but once again a balance was sought between hydrodynamic forces and experimental
throughput.
Force trigger threshold
Cell membranes can be effectively imaged at forces as low as 50-100pN; lower
forces can be used to visualize individual components on the surface of a cell
membrane.39 For force mapping, forces are typically used around the nano-newton
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Figure 2-1.

Representative AFM images of normal HPNE cells.

These images depict normal cell morphology (top), modulus mapping (middle) and
adhesion mapping (bottom). Note the underlying cytoskeletal structure made visible in
the modulus mapping image.
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range,105 however going much higher risks damaging the cell membrane. It was decided
to prevent damage to the cell surface to use a lower setpoint which still gave adequate
contact and membrane deformation, which was determined through initial calibrations to
be 400pN. Using this value yields a factor of safety of at least 2.5, assuming that
membrane ruptures can occur at forces as low as 1nN.
Ramp size
This value defines the vertical height that the cantilever moves over the entire
ramping process (from approach to full retraction). This value needs to be high enough to
ensure total separation from the surface of the cell membrane, while at the same time
ensuring that the piezomotor is not taken out of range of the machine's detection area.
Since the Bruker BioScope Resolve has a maximum Z-range of 21.3μm, it was necessary
to find a middle ground between these two extremes. PDAC cells can vary in height some cells were measured to be nearly 20 microns in height (this was especially the case
with HPAF-II cells). To ensure that all points were properly analyzed while keeping the
ramp within range of the piezomotor vertical limits, a ramp size of 4μm was chosen.
Probe used
For these experiments, a novel, specialized probe was chosen from Bruker - the
PFQNM-LC probe. These pre-calibrated probes are specifically designed to work with
live cells, and with proper calibration can produce high-resolution images of structures on
the surface of a cell. In addition, due to their larger tip diameter (approximately 130nm),
there is a reduced concern with potential damage to the cell membrane, as the forces
applied will be spread out over a larger area as compared to conventional AFM probes.46
Based on this applied force and the average spring constant of around 80pN/nm, an
estimated 5nm cantilever deformation is expected with each ramp.
As mentioned previously, PFQNM-LC probes are pre-calibrated. Specifically,
their spring constants have already been quantified before being shipped. This simplifies
the traditional calibration process to a single step: using these probes, one only needs to
place the probe on the AFM, then immerse in fluid, enter the spring constant, and
calibrate the deflection sensitivity. The probe is then ready for use.
Although other probes were considered for these studies, it was quickly
determined that they did not have appropriate characteristics for whole-cell force
analysis. Initial tests were conducted using PEAKFORCE HIRS FA probes, which are
typically used for very high-resolution (i.e., molecular) imaging in fluid. However, it was
quickly determined that these tips are too sharp (approximate tip radius of 1-2nm) for cell
imaging, as they gave images of variable and inconsistent quality. They were switched
for MLCT-BIO probes, which are designed for use with biological samples. Although
MLCT probes are more well-suited to biological samples than the PEAKFORCE HIRS
probes, with a larger tip radius of approximately 20nm, the tip height was only around 34 microns. This became an issue with whole cell scans, as due to the height of some of
the cells scanned, the cantilever itself could come into contact with the cell, leading to an
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increased risk of artifacts in the data acquisition or even potentially detaching cells from
the surface of the plate. By contrast, the PFQNM-LC probes have a tip height of almost
17 microns, significantly reducing this concern for whole cell analysis on all but the
largest cell lines.
Analysis Method
In this study, two methods of analysis were used: a whole cell analysis (consisting
of an area equal to at least 75% of the surface area of a cell), and component-based
analyses (at the nuclear, cytoplasmic, and peripheral regions). These two methods are
highlighted in Figure 2-2. This second method was accomplished by taking equally sized
readings (25 square microns) randomly at each of the three areas. The nuclear region was
defined visually on each cell as the highest point of the cell - this typically correlated with
the softest area as well, as the nucleus tends to be the softest region of a cell overall.106,107
Approximately midway between the nuclear region and the edge of the cell a random
area was selected for the cytoplasmic region, then a random area was selected for the
peripheral region of the cell. Data was analyzed using NanoScope Analysis software
(Bruker). Multiple biological replicates were conducted to enhance the reproducibility of
these results.
Aggregation Assay
Aggregation assays were performed using a slightly modified variant of a
previously described protocol.18 In brief, cells were trypsinized using 0.01% trypsinEDTA (Gibco), centrifuged and counted. They were then resuspended in enough media
to give a concentration of 1,000 cells per microliter. Then, 20 μL (20,000 cells) of cellcontaining media was pipetted onto the inside surface of a 35mm dish lid, and this was
suspended over the dish, with 3 mL of PBS added to prevent evaporation. The dish was
placed back into a humidified 37oC incubator and kept overnight. The next day, the cells
were gently pipetted to break up any loose clumps, and the cells were promptly examined
under a microscope at 20X magnification. A schematic of this experiment is shown in
Figure 2-3.
Statistical Analysis
Analyses were conducted using unpaired, two-tailed Student's T-tests to assess the
difference between relevant groups in the various experiments. All error bars used in the
attached figures indicate the standard error of mean (SEM). The number of stars used on
each graph relates to the level of significance. Items with four stars (****) indicate Pvalues below 0.0001.
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Figure 2-2.

Schematic overview of different analysis methods used in this study.

Cells were scanned and analyzed for overall data (taking an average value of at least 75%
of the surface of the cell) or in a compartmentalized manner (measuring data in equally
sized, randomly selected portions of the nuclear, cytoplasmic, and peripheral regions).
Reprinted from final submission with permission from Elsevier. Massey AE, Doxtater
KA, Yallapu MM, Chauhan SC. Biophysical changes caused by altered MUC13
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Figure 2-3.

Schematic overview of aggregation assay.
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Results
We first investigated the baseline characteristics on a panel of normal and
cancerous pancreatic cells. Figure 2-4 outlines the results of analyzing this panel
of cells. All cancerous cells were considerably softer than the reference normal
cell line (HPNE). In addition, there is a noticeable trend in the cell lines with
reduced differentiation status – a further reduction is seen in MIA PaCa-2, AsPC1 and Panc-1 as compared to HPAF- II and BxPC-3, which are poorly
differentiated and more well differentiated respectively.102 Some minor
differences were also seen in the membrane adhesiveness between these cells, but
in comparison to the large changes in membrane rigidity these were relatively
minor. Representative force maps for these cells (shown in Figure 2-4 C) clearly
show the difference in cellular rigidity and adhesion between these cell lines.2
The only set of cells with no significant differences in modulus is HPAF-II and
BxPC-3. Overall, these well-differentiated cells are significantly more rigid than the
poorly differentiated cells (MIA PaCa-2, AsPC-1, and Panc-1). In addition, both MIA
PaCa-2 (primary tumor) and AsPC-1 (metastatic cells) were found to be significantly
more rigid than Panc-1 (primary tumor). Overall adhesion data also shows a significant
reduction for most pancreatic cancer cells (except for HPAF-II) in comparison to HPNE.
There is some significance between the more well differentiated cells and the poorly
differentiated cells, however this is a much lower level of significance than what is seen
with the modulus data. Also, not all cells are significantly lower.
Figure 2-5 shows the regional data of these cells. The results for the modulus data
are very similar across all regions of the cell and are nearly identical in their trends to
what was shown in the overall analysis. Perhaps the most notable changes are seen in the
adhesion data. Although the values are not significant, trends can still be observed. Of
note, BxPC-3 has a noticeably lower adhesion as compared to HPAF-II, and AsPC-1 has
a consistently lower value than all other cell lines. If looked overall, however, MIA
PaCa-2 seems to have a slightly lower membrane adhesiveness than AsPC-1, although
this was not a significant difference. This variation between AsPC-1 and MIA PaCa-2
adhesion may be partly due to the influences of randomly selected regional data as
compared to the averaging effect seen with overall analyses. The adhesion data on the
AFM also appears to correspond well with the aggregation data shown (Figure 2-6).
Specifically, HPNE cells were observed to form small spheroids after only an overnight
incubation. HPAF-II and BxPC-3 both seem to form thin sheets of adherent cells. For the
poorly differentiated cells, MIA PaCa-2 shows large clumps of cells, then Panc-1 and
AsPc-1 show clumps that are somewhat smaller. This overall indicates a similarity in the
AFM's ability to measure cell membrane adhesion and a cell's ability to aggregate in
suspension. The more poorly differentiated cells have the lowest values and are also the
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Figure 2-4.

Characterization of normal and cancerous pancreatic cells.

(A) Modulus data for a panel of normal and cancerous pancreatic cells. (B) Adhesion
data for the pancreatic cell panel. (C) Representative force images showing relative
changes in physical parameters between cell lines.
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Figure 2-5. Regional cell data showing biophysical differences between normal
and cancerous pancreatic cells.
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Figure 2-6. Representative 20x images for aggregation assays conducted on
normal and cancerous pancreatic cells.
Note the spheroid-like formation present only in HPNE cells, while the more poorly
differentiated cells exhibit the lowest aggregative potential.
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least able to aggregate with one another.
Discussion
This data demonstrates the capability of nanoindentation analyses to clearly
discriminate between cancerous and non-cancerous pancreatic cells in vitro. It shows that
these measurements can differentiate between cell lines of differing invasive and
metastatic potential based on their phenotypic expression. Cells that are more poorly
differentiated are clearly less rigid than their more well differentiated counterparts, and
all cancerous cells are significantly less rigid than the normal epithelial cell line (HPNE).
The analysis shown in Figure 2-4 brings up some interesting observations. We
can clearly see that HPNE cells are much more rigid than all other cells tested. This is in
agreement to the previously mentioned literature consensus of reduced cell rigidity seen
in cancerous cells compared to healthy ones for a given tissue.108 Some examples of
previous studies highlighting reduced modulus in cancerous cells is shown in Table
2-2.76,78,82,109,110 We can also see a general trend correlating the differentiation status of
PDAC cells to rigidity. As mentioned previously, the more well differentiated the cell is,
the higher its modulus.
Although not as significant, a similar trend can be seen with adhesion. HPAF-II
cells did not show a large (or significant) difference from HPNE cells in terms of
membrane adhesion, although BxPC-3 were lower than both of these cell lines. MIA
PaCa-2 cells did not have a large difference from BxPC-3, while AsPC-1 and Panc-1
showed somewhat lower membrane adhesiveness, with AsPC-1 showing the lowest when
examining the cell compartmentally – with overall analysis, MIA PaCa-2 cells were
slightly less adhesive. Although not as significant as the modulus data, there were still
some positive correlations between this adhesion data and a set of aggregation assays.
Notably, HPNE cells exhibited the ability to form small spheroids, indicating a high
degree of cell-cell adhesion, whereas all other cancerous cell lines tested showed varying
degrees of reduced adhesion, with the lowest being observed with the poorly
differentiated cells. This is best represented visually by the shift in inherent aggregative
capability between more well differentiated cells (HPAF-II and BxPC-3), which show
some level of coherent, sheet-like interaction, and the poorly differentiated cells, which at
best showed loose clumping. Since it has been shown that metastasis is typically
associated with lowered cell adhesion111, measuring cell membrane adhesiveness could
give an early indicator of a metastatic shift, potentially even at the tissue level.
Regarding the AFM analysis, several points can be brought up with regards to the
experimental parameters. It was decided that using a resolution of 128*128 pixels would
allow for a greater level of data to be collected on individual cells, and give further
insight into physical properties at different regions of the cell. This is clearly visualized in
the force maps seen in the figures throughout this report. Although a higher resolution
could have been attempted, this value was chosen in an attempt to keep the cells from
suffering excessive effects in an atmosphere without constant CO2 influx. Since a
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Table 2-2.
Summary of previously published studies showing reduced modulus
in cancerous cell lines compared to normal reference cells.
Cell type

Average normal cell
modulus (kPa)

Average cancer cell modulus (kPa)

Liver

L02: 0.174

HepG2: 0.063;
Bel7402: 0.154

Breast

A184: 2.26 ± 0.560

T47D: 1.2 ± 0.28
MFC7: 1.24 ± 0.46

Prostate

PZHPV-7: 3.09 ± 0.84

LNCaP: 0.45 ± 0.21
Du145: 1.36 ± 0.42
PC-3: 1.95 ± 0.47

Ovarian

IOSE: 2.472 ± 2.048

HEY: 0.884 ± 0.529
HEY A8: 0.494 ± 0.222

Bladder

HCV29: Approx. 15
(400nm indentation)

HTB-9, HT-1376, T24: Approx. 4
(400nm indentation)

Melanocyte

HEMa-PL: 14.28

WM793: 10.18
WM115: 9.68
WM239: 6.95
WM266-4: 8.84
1205Lu: 7.29
A375P: 5

Data Sources
Bobrowska J, Awsiuk K, Pabijan J, et al. Biophysical and Biochemical Characteristics as
Complementary Indicators of Melanoma Progression. Anal Chem. 2019;91(15):98859892. doi:10.1021/acs.analchem.9b01542.
Lekka M. Discrimination Between Normal and Cancerous Cells Using AFM.
Bionanoscience. 2016;6(1):65-80. doi:10.1007/s12668-016-0191-3.
Lekka M, Gil D, Pogoda K, et al. Cancer cell detection in tissue sections using AFM.
Arch Biochem Biophys. 2012;518(2):151-156. doi:10.1016/j.abb.2011.12.013.
Pei W, Chen J, Wang C, et al. Regional biomechanical imaging of liver cancer cells. J
Cancer. 2019;10(19):4481-4487. doi:10.7150/jca.32985.
Ramos JR, Pabijan J, Garcia R, Lekka M. The softening of human bladder cancer cells
happens at an early stage of the malignancy process. Beilstein J Nanotechnol.
2014;5:447-457. doi:10.3762/bjnano.5.52.
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256*256 image using the previously described parameters would take almost 90 minutes
to conduct, it would reduce the throughput of this analytical system by roughly fourfold.
The current resolution allows for at least three replicates for every plate used within less
than two hours of taking the plate out of the incubator, accounting for cell transport and
machine calibration.
An interesting trend can be drawn in the cells with a known MUC13 expression.
Of the cells used in this study, Panc-1, BxPC-3 and MIA PaCa-2 are known to have a
minimal MUC13 expression, AsPC-1 has a moderate expression and HPAF-II has a high
expression. It seems that cells with a higher modulus tend to have a higher MUC13.
However, this alone does not explain this increased modulus, otherwise one would expect
that BxPC-3 and MIA PaCa-2 cells should be softer than they were recorded to be.
It was originally thought that metastatic cells would have a lower modulus when
compared to the primary tumor. However, based on the data shown, that does not appear
to be the case. BxPC-3 and HPAF-II are nearly identical in their modulus values, and
although AsPC-1 is significantly softer than MIA PaCa-2, it is significantly higher than
Panc-1. This comparison should be taken cautiously however, considering that these cells
were all collected from separate patients. Furthermore, since the cells show a clear
pattern of rigidity based on differentiation status, we can potentially relate this to the
overall state of EMT/MET. Cells that are more well-differentiated are typically thought
to be closer to an epithelial state, while the more poorly differentiated it is the more
mesenchymal it becomes.96,112,113 Because of this, we can see the physical differences
between these cells as a potential physical marker of its overall aggressiveness. This
could potentially be applied to the tissue level, and if an abnormal or unknown tissue
section is found to have a considerably different set of physical properties than normal
adjacent tissue, it could be an early warning sign of aberrant or cancerous tissue. This
could help clinicians to more rapidly diagnose the patient or potentially have ideas on
therapeutic options.
Of the cells tested, BxPC-3, MIA PaCa-2, and Panc-1 are all primary tumors,
while HPAF-II and AsPC-1 are metastatic. When comparing some of the metastatic cells
to primary tumor cells, we see that overall the metastatic cells have a larger modulus
(MIA PaCa 2 notwithstanding). It is possible that this can be related to a cell's EMT/MET
state. If these PDAC cells were treated with agents to trigger either EMT or MET, a
baseline could be established between these phenotypes and how they affect physical
properties. Regarding metastatic cells, it seems likely that if these have already
established themselves at a metastatic tumor site, they could have undergone a
mesenchymal-epithelial transition (MET) and reversed some of the reductions in modulus
that have been previously shown with EMT induction.80 However, since these cells are
not isogenic this cannot be directly confirmed. It is possible that this comparison is a
biophysical representation of the MET process, albeit in a different cancer tissue.
Curiously, they showed a lower overall adhesion, although this may be due to differences
between the physical properties of CRC and PDAC cells.
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Of interest, in more rigid cells (particularly HPNE), the modulus maps seem to
visualize the underlying cytoskeletal structure (see Figure 2-1). This was seen in some of
the other cells as well, such as a few MIA PaCa-2 and AsPC-1 cells, but not across all
cell lines.
The results shown in this chapter can be of strong interest in a clinical and
diagnostic sense. It is possible that similar tests can be run in the future on patient-derived
tumor tissues, and when compared to adjacent normal cells, biophysical differences may
be able to assist in expediting tumor grading, and possibly even metastatic risk and an
overall prognosis of the disease state. Similar results have already been suggested in other
cancers at the tissue level.59,78
It should be noted that there is some discrepancy when comparing the results of
the regional and overall analyses (Figures 2-3 and 2-4). This is partly due to the amount
of the cell that is measured with each method. In the overall analysis, at least 75% of the
entire cell is quantified, and an average value is taken for each individual cell. When
using the regional analysis method, only 25 square micron regions are randomly taken at
either the nuclear, cytoplasmic or peripheral region. Although they can give a
representative idea of these values, especially with multiple replicates, the overall data
takes more of the cell surface into effect, and variations across the cell surface (especially
regions closer to the nucleus, which tends to be softer as mentioned previously) may
lower the overall average value seen at different regions when compartmentalized. Given
the heterogeneity of the biophysical properties on a cell surface, the regional method may
be less representative when compared to the overall method, and lead to a greater intersample variation than the overall analysis.
The method of analysis (overall cell analysis as compared to analyzing nuclear,
cytoplasmic, and peripheral regions separately) seems to have an impact on the results.
Of note, the trends in cell rigidity discussed here are virtually identical across both
methods of analysis - the same patterns were seen whether the cells were broken up into
subcomponents (nuclear, cytoplasmic, and peripheral sections) or analyzed overall. By
contrast, there are some minor differences in the membrane adhesion when considered
overall and regionally, however neither method of analysis shows considerable
significance across any of the cell lines. This is partly due to the lower variation between
cell lines in adhesion values as compared to the modulus data. One exception was seen
when examining the cells overall - MIA PaCa-2 was found to have the lowest membrane
adhesiveness, while when looking at subcomponents, AsPC-1 was lower. AsPC-1 was
significantly lower than all other cells at most regions; while MIA PaCa-2 was
significantly lower than all cells except AsPC-1 when examined overall. Overall, HPAFII cells show a slightly smaller adhesion when compared to HPNE cells, albeit not
significantly. BxPC-3 also shows a significantly lower adhesiveness to HPAF when
measured overall, but not compartmentally.
As seen in the subdivision chart, there is a general trend of increasing rigidity the
closer the measurements are taken to the periphery of a cell. This may be in part due to
structural changes and the underlying cellular components at various regions of the cell.
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By contrast, the cell adhesiveness appears to have minimal if any difference when
compared across different regions of the cell surface.
Lastly, it is worth noting that although the probe was calibrated and all values are
quantified and consistent over multiple tests, the adhesion data shown on these tests
should not be considered quantitative. This caveat is mentioned as the adhesion data in
these charts represents the adhesive interaction between the cellular membrane and a
bare, unmodified silicon nitride AFM tip. This interaction between the silicon nitride tip
and cell membranes is not one that will be found in the body, and the exact mechanisms
of membrane attachment to this material is not well understood, although it is known that
the adhesive interaction between this material and cellular membranes is relatively
weak.114 Although it can still give some insight into the base adhesiveness of the
membrane, it is not representative of an interaction that a cancer cell would biologically
undertake. Therefore, it should only be seen as suggestive as to the adhesive potential of
a cell rather than an exact, quantifiable result.
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CHAPTER 3. EFFECT OF CHEMOTHERAPEUTICS ON BIOPHYSICAL
PROPERTIES OF PANCREATIC CANCER CELLS
Introduction
PDAC has one of the highest mortality rates among cancers, with a poor survival
rate of less than 10%.6 Even with recent advances in chemotherapeutics, the overall
survival from this disease state has not dramatically improved over the past few
decades.115 Various chemotherapeutics have been used to address pancreatic cancer current first line agents for PDAC include the combination of gemcitabine and albuminbound paclitaxel (nab-PTX) or the FOLFIRINOX (irinotecan, oxaliplatin, leucovorin, 5fluorouracil) regimen.116,117
In this chapter, three agents were selected and used to measure their biophysical
effects on PDAC cells: gemcitabine (GEM), a first-line agent; paclitaxel (PTX), a
second-line agent that has been shown to enhance the effects of GEM; and curcumin
(CUR), a natural product derived from turmeric that has shown promising effects for
PDAC therapy.118,119 Our aim was to show the biophysical effect of these drugs a panel of
PDAC cells to see how varied stages of differentiation respond to treatment
biophysically. Initially, we anticipated more poorly cells would be more susceptible to
treatment (i.e., exhibit higher changes in their biophysical properties). We also
anticipated that, due to its mechanism of action, PTX would lead to the greatest change in
these cells.
Pharmacological Agents Used and Their Characteristics
Paclitaxel (PTX)
A taxol agent, PTX works by promoting microtubule assembly through enhancing
tubulin dimer action, stabilizing existing microtubules, and inhibiting disassembly - this
in turn interferes with the G2 phase of mitosis, inhibiting cell replication.120 Although not
used as a monotherapy in PDAC, when used as an albumin-bound nanoparticle (e.g.,
Abraxane), it has been shown to increase the therapeutic efficacy of first-line GEM via
inhibiting the enzyme cytidine deaminase, which is involved in breaking down GEM
once it enters the cell.121 This combination of nab-PTX and GEM is one of the standard
first line therapies currently in use.116 Given this mechanism of action, PTX was
originally considered the positive control, as we expected it would cause the greatest
biophysical effect in the cells being analyzed.
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Gemcitabine (GEM)
A pyrimidine antimetabolite, GEM (Figure 3-2) inhibits DNA synthesis via
inhibiting DNA polymerase and ribonuclease reductase. It is phosphorylated
intracellularly into a monophosphate form by deoxycytidine kinase. After a further
conversion into the diphosphate form, GEM inhibits DNA synthesis via ribonucleotide
reductase inhibition, while the triphosphate form incorporates into DNA and inhibits
DNA polymerase.122 Of note in pancreatic cancer, GEM is seen as a first-line agent,
however it is only associated with a marginal increase in patient survival.123 There is also
concern of rapid resistance to this drug124, although combinations, such as the nabPTX/GEM system as mentioned previously, are being investigated to overcome this.125
Curcumin (CUR)
CUR is a yellow pigment derived from turmeric, a spice derived from the
homonymous rhizome, Curcuma longa. Multiple studies have shown it to possess
antioxidant, anti-inflammatory, and anticancer properties. Recent research has shed light
on the actions of this agent in cancer, with effects potentially including modulating cell
cycle, apoptotic signaling, protein kinases, NF-kB, proteasome activation, epigenetic
regulation and histone modification. There are some concerns over the low bioavailability
of the drug, however a recent dosage form (known as THERACURMIN126) has been
developed to help bypass this concern.118,127,128
Methods
Cell Culture
Pancreatic cancer cells were acquired from ATCC. These cells were grown in a
humidified 37oC incubator with a 5% CO2 atmosphere. MIA PaCa-2 and Panc-1 cells
were grown in DMEM media. BxPC-3 and AsPC-1 cells were grown using RMPI-1680
media. HPAF-II cells were grown using DMEM/F-12 media. All types of culture media
were acquired from Gibco and supplemented with Fetal Bovine Serum (Gibco) and
Antibiotic-Antimycotic (Gibco) to final concentrations of 10% and 1%, respectively.
Cells were grown in T-75 flasks until at least 75% confluent and then trypsinized,
counted, and seeded as needed for the experiments discussed in this chapter.
Live Cell AFM Data Analysis
Cells (HPAF-II, BxPC-3, MIA PaCa-2, AsPC-1, and Panc-1) were seeded in 60
mm dishes (2*106 cells) and attached overnight. Cells were allowed to grow until they
reached 75% confluency. They were then treated with an approximate 48-hour IC50 over
a 24 hour period. The doses for PTX and CUR were experimentally determined in our
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lab129–131 (10nM for PTX and 15 μM for CUR) and 500nM was used for GEM
treatments. These doses were selected in order to ensure a therapeutic effect on the cells
but not so high as to kill and detach cells from the surface of the plate. The exact dose for
this effect in each cell line may have varied, but these values were chosen as an overall
baseline. This effect is of particular note in GEM, since certain PDAC cell lines are
considerably more resistant to GEM than others,132,133 necessitating a high enough dose
to affect these without leading to excessive cell death in the more sensitive cell lines.
PTX and CUR stocks were made in DMSO, while GEM was dissolved in PBS. Before
imaging, the cells were washed with PBS three times and fresh media was added. The
dish was taken to the AFM and placed on a heated stage (37oC) and equilibrated for 15
minutes. Using custom-generated PFQNM-LC cantilevers (tip diameter ~130nm46)
designed for live cell applications (Bruker), the deflection sensitivity was calculated via
thermal tune. For nanoindentation, a force curve was first generated on the center of a
cell to confirm contact, then a force volume scan was conducted (128*128 resolution,
512 samples per ramp, 15Hz ramp rate, 400pN force trigger, 4μm ramp size) to generate
a force map of the entire cell. An in-depth explanation for these parameters is mentioned
in Chapter 2.
After collecting data on multiple cells, the nanomechanical properties (elastic
modulus, or stiffness, and adhesion) were calculated at the nuclear, cytoplasmic, and
peripheral regions and averaged. An overall analysis was also conducted. All force data
analysis was conducted using NanoScope Analysis software (Bruker).
Statistical Analysis
Analyses were conducted using unpaired, two-tailed Student's T-tests to assess the
difference between relevant groups in the various experiments. All error bars used in the
attached figures indicate the standard error of mean (SEM). The number of stars used on
each graph relates to the level of significance. Items with four stars (****) indicate Pvalues below 0.0001.
Results
Significant changes could be detected using biophysical analyses, but significance
was mostly seen only in poorly differentiated cells. For the more well differentiated cell
lines, HPAF-II and BxPC-3, there was no significant effect seen at any point on the cell
for PTX treatment, although a slight decrease in cell rigidity was still observed. An
overview of the overall changes is depicted in Figure 3-1.
Looking at the cells individually, more specific patterns can be seen regionally.
With the well-differentiated cells, the overall effect of PTX, CUR, and GEM is relatively
similar: in HPAF-II cells, there is a minimal effect with PTX treatment on cell rigidity,
while a small yet significant increase was noted with CUR treatment at the periphery of
cells. Curiously, GEM treatment reduced the cell modulus, and was significant at the
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Figure 3-1. Overall biophysical data of pancreatic cancer cells treated with
paclitaxel (PTX), curcumin (CUR), and gemcitabine (GEM).
The doses used were 10nM PTX, 15μM CUR and 500nM GEM.
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nuclear region (Figure 3-2). BxPC-3 cells exhibited very few significant changes at the
regional level, the most notable being a significant decrease at the periphery with GEM
treatment (Figure 3-3).
For poorly differentiated cells, more significant effects were observed. In MIA
PaCa-2 cells, no significant effect was observed with PTX treatment, and again a slight
decrease was seen with GEM treatment (significant at the periphery). Of interest, CUR
treatment led to a significantly higher modulus across the cell surface as compared to
vehicle control (Figure 3-4).
Considerably more significant effects were seen in the poorly-differentiated
AsPC-1 and Panc-1 cells. With AsPC-1, significant increases were seen across the cell
surface with all three treatments, with the largest increase again seen with CUR. PTX had
a significant increase at the nuclear and cytoplasmic regions but was not found to be
significant at the periphery (Figure 3-5).
Lastly, in Panc-1, noticeably larger increases were noted in all three drugs. All
regions of the cell were significantly more rigid than control, and again the greatest
overall increase was noted in CUR. In fact, based on these results the greatest effect on
increasing cellular rigidity occurs over all regions of AsPC-1 and Panc-1 cells treated
with CUR, in each case representing a nearly 4-fold increase (Figure 3-6).
Overall, the largest increase in cell rigidity was noted in CUR treated cells. Also,
the greatest physical changes were seen in poorly differentiated cells – particularly in
Panc-1 and AsPC-1 cells.
Discussion
It has been mentioned in past research that poorly-differentiated tumors (i.e.,
higher grade tumors with an increased proportion of stem-like cancer cells) tend to be
more drug resistant as well as being associated with poor prognosis134–138, however based
on the results shown in this chapter, the poorly-differentiated cancer cell lines show a
greater biophysical change as compared to moderate and well-differentiated PDAC cell
lines. This is of some interest, as some evidence has supported the notion that the more
poorly differentiated a PDAC cell line is, the more thorough the associated EMT markers
are expressed.96 This gives some insight to the relation between cellular phenotype and
the overall mechanics of the cell.
Although it is traditionally considered one of the first-line agents, GEM was
shown to have the lowest overall biophysical effect on PDAC cells. Previous studies from
our lab have shown that GEM does have an effect on PDAC cell motility and other
pathways, however the effect was only marginal at best - it was however shown to be
enhanced by the addition of other agents, including CUR and ormeloxifene (ORM). It
should be noted however that the doses used in these studies are lower than what was
used in this trial - however the effect of these lower doses (100nM and 200nM) also had
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Figure 3-2. Regional biophysical analysis of HPAF-II cells treated with PTX,
CUR, and GEM.
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Figure 3-3.
and GEM.

Regional biophysical analysis of BxPC-3 cells treated with PTX, CUR,
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Figure 3-4. Regional biophysical analysis of MIA PaCa-2 cells treated with PTX,
CUR and GEM.
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Figure 3-5.
and GEM.

Regional biophysical analysis of AsPC-1 cells treated with PTX, CUR,
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Figure 3-6.
and GEM.

Regional biophysical analysis of Panc-1 cells treated with PTX, CUR,
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minimal effect on cell toxicity, which may explain why so little effect was seen on cell
motility.94,129
Interestingly, the greatest biophysical changes appear to be caused by CUR.
Originally, we anticipated that PTX, an agent known to hyperstabilize microtubules,
would cause the greatest physical change at its respective 48-hour IC50 dose, essentially
making it a positive control for the study. However, it appears that CUR has a more
significant effect, especially on the more poorly differentiated cell lines. In fact, the
relative increased modulus in AsPC-1 and Panc-1 cells was much higher in CUR-treated
cells as compared to those treated with PTX. This difference in PTX and CUR was most
notable in AsPC-1: while PTX led to an overall increase in modulus of approximately
50% at its IC50, CUR led to a nearly 4-fold increase in rigidity.
It should be noted that the doses for these agents were chosen to be as close to the
IC50 values of all cell lines. There may be a certain level of variation based on the cell
line, and furthermore the therapeutic effect may be more readily observed based on the
biophysical change itself - for instance, HPAF-II cells were shown to have a higher IC50
than Panc-1 cells for PTX131, and this positively correlates with the increased modulus in
Panc-1 cells compared to HPAF-II with PTX treatment.
Although the more poorly differentiated cells have a greater physical effect with
the chemotherapeutics, this may not necessarily translate to an increased therapeutic
efficacy. As noted in recent research by Khan et al, HPAF-II and Panc-1 cells were
treated with CUR at the same dose used in this study (15μM), although their results
indicated a greater therapeutic effect on HPAF-II cells, as fewer cells were seen on both
MTT and colony formation assays compared to Panc-1.129 This may indicate that the
correlation between therapeutic efficacy and physical changes is drug (and cell) specific.
Limited information in the literature could be found as a direct comparison in
terms of articles dealing with measuring the biophysical effects of these drugs on other
cancer cells, but most of what was available agreed with the consensus that treatment
leads to an increased rigidity. A brief summary of previous studies dealing with PTX and
CUR can be seen in Table 3-1.139–141 Of note, one study indicated a reduced modulus
with CUR treatment in breast cancer cells, indicating a possible tissue-specific
response.141 No studies were found quantifying the biophysical effects of GEM treatment.
Adhesion data for the cell treatments was not as significant when compared to
modulus changes. Considering the caveats discussed in Chapter 2, these results should
also be taken with caution as they may not be truly representative of the actual effects of
these drugs. In addition, the effects noted are somewhat contradictory to the originally
expected result - initially, it was thought that most treatments would increase the
adhesiveness of cells, which could potentially be related to a reduced metastatic potential.
This was seen with HPAF-II cells and PTX treatment, however no modulus increase was
noted with this same dose; by contrast, Panc-1 cells actually showed a decreased
adhesion with CUR and GEM treatment which was the opposite of our anticipated result.
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Table 3-1.
Summary of previously published studies detailing the biophysical
effects of PTX and CUR in cancer cell lines.
Cell line

Average control
modulus (kPa)

Average treatment
modulus (kPa)

HEPG2
(Liver cancer)

1.33 ± 0.034

3.4 ± 0.26
(CUR Treatment, 1.56
μg/mL)

PC-3
(Prostate cancer)

Approx. 4

Approx. 8.5 (PTX
Treatment, 2 μM)

MCF7
(Breast cancer)

9.5 ± 2.2

5.8 ± 1.1 (CUR
Treatment, 20 μM)

Data Sources
Olugbami JO, Damoiseaux R, France B, et al. Atomic force microscopy correlates
antimetastatic potentials of HepG2 cell line with its redox/energy status: effects of
curcumin and Khaya senegalensis. J Integr Med. 2017;15(3):214-230.
doi:10.1016/S2095-4964(17)60337-6.
Ren J, Huang H, Liu Y, Zheng X, Zou Q. An Atomic Force Microscope Study Revealed
Two Mechanisms in the Effect of Anticancer Drugs on Rate-Dependent Young’s
Modulus of Human Prostate Cancer Cells. Dague E, ed. PLoS One.
2015;10(5):e0126107. doi:10.1371/journal.pone.0126107.
Saab M, Bec N, Martin M, et al. Differential Effect of Curcumin on the Nanomechanics
of Normal and Cancerous Mammalian Epithelial Cells. Cell Biochem Biophys.
2013;65(3):399-411. doi:10.1007/s12013-012-9443-1.
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In most of the other treatments on other cells, no significant differences in adhesion were
noted (Appendix A; Figure A-1).
It should be noted that not all drugs will act to increase the modulus of a cell. This
is partly based on the mechanism of action, such as the previously mentioned "positive
control" that was PTX, acting to stabilize microtubules leading to an increased cell
rigidity. However, previous research has shown that some agents known to destabilize
microtubule structure can lead to a decrease in fibroblast cell modulus with treatment.142
Similarly, a recently developed anti-tubulin agent, VERU-111, which is a βIII/βIV
tubulin inhibitor143, was shown to lead to signficant reductions in cell rigidity in cervical
cancer cells using the same procedures outlined in this study. Nanoformulations were
also shown to have superior effects to free drug in other experiments performed in our
lab, including nano-VERU on cervical cancer cells. A clear trend was noted in a
reduction of the modulus from untreated, free drug, and nano-VERU. (Figures A-2 and
A-3). This demonstrates the importance of understanding the mechanism of a drug to
ensure that the observed biophysical effect is a cause of the drug or a possible response
related to drug resistance.
In a fundamental sense, the biophysical effect of these agents can be ascribed to
the action of chemotherapeutics. These drugs tend to act on more rapidly dividing cells,
and the fact that the poorly differentiated cells exhibit larger physical changes would
agree with this notion.
DMSO (dimethyl sulfoxide), a commonly used solvent in biochemical
experiments, is not without its effects on cancerous cells. It has been known for several
decades that it can impart effects on various cancer cells - data has suggested that even in
PDAC cell lines, at concentrations as low as 2% it can inhibit colony formation, reduce
alkaline phosphatase, and reduce attachment to collagen.144 Although the highest DMSO
concentration used in these studies was only 0.2%, there is still evidence of some effect
on the biomechanics of these cells, at least in the more poorly differentiated cell lines.
The most apparent example of this can be seen in Panc-1 cells treated with the DMSO
vehicle for PTX. By contrast, the vehicle for CUR treated cells was a concentration of
only 0.1%, and the effect was minimal across all cell lines.
The results of this chapter can be of great interest clinically, as it gives a rapid
method of determining therapeutic efficacy of various drugs or natural compounds.
Similar studies have previously demonstrated the ability to measure biophysical effects in
various cancers after being treated.145–149 Given a general understanding of their
mechanism of action, one can predict the physical effect on a cell and measure it, either at
the cellular or tissue level. This level of change (whether an increase or decrease, again
partly based on the mechanism of action of the administered agent) can indicate
therapeutic efficacy or possibly an indication of drug resistance.
Biophysical analyses can also be used to detect the efficacy of nanoformulations
and potentially see whether or not they have superior physical effects on cells as
compared to free drug. A recent publication from our lab has shown a significantly
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increased rigidity in both cells and tissue sections with a magnetic nanoparticle
formulation of CUR (MNP-CUR). Interestingly, the greatest change occurs in Panc-1
cells, which agrees with the free drug analysis shown in this study. In addition, MNPCUR seemed to show a superior effect in reducing cell aggressiveness by various motility
assays and various biochemical tests, as well as an enhanced effect in vivo. Biophysical
effects for this formulation could even be seen in excised tissue sections.129 (Figure A-4)
Further indications of superior therapeutic efficacy can be seen in PDAC with
nanoformulations of PTX. Specifically, a recent nanoparticle formulation of PLGA-PTX
as made by our lab showed a significant increase in the modulus with nanoparticle
treatment. We also used the AFM to help characterize the particles - in agreement with
DLS results, we indicated a relatively consistent size for drug loaded and control PLGA
nanoparticles. In addition, these particles were shown to have no significant physical
changes with drug loading, which seems to support the notion that encapsulation was
achieved as seen with FTIR and XRD results.131 (Figures A-5 and A-6).
As mentioned in Chapter 2, there may be some variation in the values when
comparing regional and overall data. This was noticeable in HPAF-II cells, where some
differences were noted in the trends for CUR treatment, albeit not to a significant degree.
The trends in both cases are still similar even with the variations – this can be explained
in part due to the nature of the overall analysis. Discrepancies were also noted in MIA
PaCa-2 cells, however they were somewhat larger. Notably, the effect of CUR was found
to be significant at the compartmental level but not overall. Furthermore, it was noted that
MIA PaCa-2 cells had significant changes in modulus with successive passaging, leading
to larger standard deviations in the mean values. Although this was seen with other cells
to a minor extent, the effect was much more pronounced with this MIA PaCa-2. Recent
work has demonstrated that cancer cells can have different physical properties over
successive passages150, however it is unclear as to why only MIA PaCa-2 was so strongly
affected in this way. Since more of the cell is being taken into consideration, the average
value will be lower since most of the cell has a lower modulus value than the peripheral
region.
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CHAPTER 4. EFFECT OF MUC13 MODULATION ON BIOPHYSICAL
PROPERTIES OF PANCREATIC CANCER CELLS3
Introduction
Pancreatic cancer (PanCa) remains one of the deadliest cancers and leading
causes of cancer-related death in the United States, requiring additional research to
improve quality of life and survival rates. As of 2018, over 44,000 deaths were estimated
out of around 55,000 new cases representing a nearly 80% mortality rate.6 Even with
recent advances in surgical techniques, chemotherapeutic regimens and radiation
therapies, there is a poor 5-year survival rate of less than 10%.10 One critical factor in this
disease is the aberrant expression of various mucins.22 These high molecular weight
glycoproteins are normally expressed on the exterior of mucosal surfaces to act as a
protective barrier with the surroundings.21
One mucin of note is MUC13, a transmembrane mucin which is normally
expressed at low levels in the large intestine, trachea, kidney, small intestine, and gastric
epithelium. Current evidence in the literature suggests an aberrant expression of MUC13
has been associated with ovarian and gastrointestinal cancers.27 Our lab has previously
shown that the aberrant expression of MUC13 is associated with an enhanced
tumorigenesis both in vitro and in vivo in ovarian cancer18, colorectal cancer (CRC)19,
and PanCa.20 In all three cancers, MUC13 was associated with an increased cancer cell
motility as shown through enhanced proliferation, colony formation, invasion, and
migration. In addition, MUC13 was found to be significantly overexpressed in cancerous
tissues as compared to their normal counterparts, indicating a singular role in cancer
development.18,31,151 Results from PanCa and CRC studies seem to indicate that MUC13
expression is higher in both advanced-stage and metastatic tumor tissues.31,151
In order to better assess changes in a cell’s behavior, various biochemical assays
exist to elucidate the specific causes of these changes. There is great interest to
understand biophysical information at an ultrastructural level to help judge cellular
phenotypes. To accomplish this, over the past few decades a new technology has
emerged that allows for biophysical characterization of cells. This technology is based on
relatively recent advances in the field of atomic force microscopy. An atomic force
microscope (AFM) is a type of scanning probe microscope that works by taking a sharp
metallic probe attached to a flexible cantilever and bringing it into contact with or a short
distance above the sample's surface and can generate very high-resolution threedimensional topographies. Due to the direct interaction between the probe and the
sample’s surface, it is possible to use an AFM to perform additional analyses – one of the
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most widely used and promising (particularly for biological research) is quantifying
physical parameters via nanoindentation.36,152,153
With this technique, the probe is brought into contact with the sample and a set
deformation is applied. A force curve is generated, and using this, several
nanomechanical parameters can be quantified (namely, Young’s modulus109,154 and
adhesion111,155,156). Young’s modulus, also known as the elastic modulus, is a parameter
that defines a material’s stiffness, and is defined as stress (a force applied over a given
area) divided by strain (the change in a material’s length as compared to its original
dimensions). Given this parameter, it is possible to determine key physical changes – the
more force required to deform a material indicates a higher modulus, and by contrast, a
lower force to deform indicates a reduced modulus.35
The application of nanoindentation to cancer cells leads to a new and exciting
technique to help identify and potentially even diagnose cancer from a purely physical
analysis.79 The current consensus in scientific literature supports the notion that cancer
cells are less rigid (i.e., they have a lower modulus) than their healthy cellular
counterparts. In addition, cells with a higher metastatic potential have also generally been
seen to have a lower rigidity as well. 77,109 However, there is limited research on the
biophysical role of mucins and virtually none of this applied to PanCa. Therefore, we
present our findings on the biophysical effects of MUC13 via genetically modified PanCa
cells with over-expressed or knocked down MUC13 levels to determine if any significant
biophysical changes can be identified. This will then be compared to the phenotypic
effect of MUC13 on cancer cells to see if the expected correlation in literature is met
Methods
Cell Culture
Pancreatic cells (HPAF-II and Panc-1) were acquired from ATCC. These cells
were grown in a humidified 37oC incubator with a 5% CO2 atmosphere. Panc-1 cells
were grown in DMEM media and HPAF-II cells were grown using DMEM/F-12 media.
All types of culture media were acquired from Gibco and supplemented with Fetal
Bovine Serum (Gibco) and Antibiotic-Antimycotic (Gibco) to final concentrations of
10% and 1%, respectively. Antibiotic selection was used on transfected cells with every
passage. Cells were grown in T-75 flasks until at least 75% confluent and then
trypsinized, counted, and seeded as needed for the various experiments discussed in this
chapter.
Transfection of PanCa Cells for Altered MUC13 Expression
Transfected models of MUC13 modulated cells for PanCa cells were generated
using previously described protocols.20 In brief, overexpressing models were generated
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using Panc-1 cells transfected with Lipofectamine 2000 per manufacturer’s directions
(Invitrogen). Knockdown cell lines were created with HPAF-II transfected with MUC13
specific shRNA lentiviral particles per manufacturer’s instructions (Sigma).
PCR
Cells were collected and RNA was isolated using TRIzol reagent. Reverse
transcription was then conducted using High-Capacity cDNA reverse transcriptase kit
(ThermoFisher) according to manufacturer’s protocol. After collecting cDNA, it was
amplified using MUC13 and GAPDH-specific primers. Quantitative real-time PCR was
done using SYBR Green Master Mix on a Roche LightCycler.
AFM Imaging and Nanoindentation
Cells were seeded in 60 mm dishes (Sarstedt, Model No. 83.3901, Numbrecht,
Germany) and grown to 75% confluency. The cells were then gently washed with
Phosphate Buffered Saline (PBS, 1X, pH 7.4) three times and fresh media was added.
Cells were taken to the AFM (BioScope Resolve, Bruker; Billerica,MA,USA) and placed
on a heated stage (37 oC) and allowed to equilibrate for 10-15 minutes. During this time,
the probe (PFQNM-LC, Bruker) was calibrated via thermal tune. These probes are
custom-made for live cell applications and have pre-calibrated spring constants, allowing
for a simple, one-step calibration. Once calibrated, the probe was brought into contact
with a cell and a ramp test was run to confirm proper contact. A force volume scan was
then conducted over a small group of cells (128*128 resolution, 15Hz scan rate, 400 pN
force setpoint, 4 μm ramp size) and repeated on several groups. All data was collected
within a two-hour window for each plate. Force data was then analyzed in two separate
ways: firstly, over the whole cell using at least 75% of the surface of each cell, and then a
regional analysis was conducted, taking equally sized 25 μm2 regions randomly selected
at the nuclear, cytoplasmic, and peripheral regions. The data was averaged for each group
from multiple cells in each group using NanoScope Analysis software (Bruker). These
experiments were repeated in triplicate.
Aggregation Assays
To determine the effect of MUC13 on cell-to-cell adhesion, aggregation assays
were conducted. The original protocol can be found in one of our lab’s previous
publications.18 The protocol was slightly modified for use in these experiments: briefly,
20,000 cells were suspended in a small bead of media (~25 μL) which was deposited onto
the lid of a petri dish. The base of the petri dish was filled with PBS to prevent
evaporation. The lid was then placed on the dish and incubated overnight at 37 oC. The
next day the lid was inverted, and the bead was gently pipetted to disperse any larger
aggregates. Photos were then promptly taken using optical microscopes (20x images
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taken on EVOS® FLoid Cell Imaging System, Cat. No. 447136; ThermoFisher,
Waltham, MA, USA).
Statistical Analysis
Analyses were conducted using unpaired, two-tailed Student’s T-tests to assess
the differences between relevant groups in the various experiments. All error bars used in
the attached figures indicate the standard error of mean (SEM). The number of stars used
on each graph relates to the level of significance - i.e., one star (*) indicates P-values
below 0.05, two stars (**) values below 0.01, three stars (***) for values below 0.001,
and items with four stars (****) indicate all P-values below 0.0001.
Results
MUC13 modulated cells were generated using the protocols outlined in the
Methods section. Using PCR analysis, altered MUC13 expression was confirmed in these
cell lines. Of the cell lines analyzed in Chapter 2, HPAF-II was chosen for the knockout
model as our lab has previously shown it has extensive MUC13 expression, while Panc-1
has shown minimal to no MUC13 expression, making it an ideal candidate for an
overexpression model.20
Overexpression of MUC13 in Panc-1 cells (Figure 4-1) gave results that
theoretically agreed with the expected trends in literature, specifically that genetic
changes that cause enhanced invasive or migratory potential reduce the cellular
modulus.97,157 Panc-1 MUC13 OE cells were significantly softer than their vector
counterparts. Overall, there was no significant change in membrane adhesion.
A set of HPAF-II cells with MUC13 knockdown (Figure 4-2) showed the
opposite effect, i.e., an overall significant increase in was noted in the modulus as well as
a highly significant increase in membrane adhesiveness.
As discussed in the Methods section and shown in Figure 2-2, the MUC13
modulated cells were analyzed in an overall method (as seen in Figures 4-1 and 4-2) as
well as a regional method, where data was collected in equally sized regions at the
nuclear, cytoplasmic and peripheral regions. When looking at the regional data for Panc-1
MUC13 overexpressing cells, a significant reduction in the modulus was noted in the
nuclear and cytoplasmic regions, and a significant reduction was noted in adhesion but
only at the nuclear region. For HPAF-II MUC13 knockout cells, the modulus was found
to be significantly increased at the cytoplasmic and peripheral regions, and the cell has
significantly higher membrane adhesion at all regions of the cell (Figure 4-3). The data
in Figures 4-1 through 4-3 shows that the trend between the overall and regional analyses
are similar.

55

Figure 4-1.

Effect of MUC13 overexpression on PanCa biophysical properties.

(A) PCR data showing increased mRNA with MUC13 overexpressed cells. (B) Effect of
MUC13 overexpression on modified Panc-1 cell rigidity (i). Representative force maps
show changes in modulus across the surface of the cell (ii). (C) Effect of MUC13
overexpression on modified Panc-1 adhesiveness (i). Representative force maps show
changes in adhesion across the surface of the cell (ii).

Figure 4-2.

Effect of MUC13 knockdown on PanCa biophysical properties.

(A) PCR results showing reduced mRNA levels with MUC13 knockdown. (B) Effect of
MUC13 knockdown on rigidity of modified HPAF-II cells (i). Representative force maps
showing changes in rigidity across the surface of the cell (ii). (C) Effect of MUC13
knockdown on adhesion of modified HPAF-II cells (i). Representative force maps
showing the changes in adhesion across the surface of the cell (ii).
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Figure 4-3.
cells.

Regional nanocmechanical analysis of MUC13-modulated PanCa

(A) Regional nanoindentation data for Panc-1 MUC13 overexpressed cells showing
localized changes at the nuclear, cytoplasmic, and peripheral regions of the cell surface.
(B) ) Regional nanoindentation data for HPAF-II MUC13 knockdown cells showing
localized changes at the nuclear, cytoplasmic, and peripheral regions of the cell surface.
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Aggregation assays were conducted on these cell lines to determine the effect of
MUC13 on cell-to-cell cohesion. The results of these tests indicate that MUC13 plays a
potent role in affecting this intercellular adhesion (Figure 4-4). It was shown that Panc-1
cells with overexpressed MUC13 were only loosely grouped to one another, while the
vector control consistently stayed in tight clusters. HPAF-II vector cells did show some
inherent adhesiveness; however, it was observed to be in loosely connected clumps with
several detaching cells. With MUC13 knockdown, there appeared to be a greater
interconnectivity between the cells, and a clear sheet-like layer of cells was observed.
Discussion
Multiple previous studies have shown that cancer cells have a reduced modulus
when compared to their normal and noncancerous counterparts.43,78,109 In addition, factors
that enhance oncogenic phenotypes have also led to reductions in cancer cell
rigidity.74,75,97 It is thought that these changes are in part due to changes in the
cytoskeleton of the cell.73,76 Due to this, several studies have been conducted
investigating the biophysical differences in cancerous and normal tissue as a means of
rapid identification and diagnosis of cancer.78,108,158
Although various studies have been published detailing the biophysical effects of
various genetic alterations or treatment with various compounds in both PanCa97,148,159
and other gastrointestinal cancers such as CRC160, there has been no study to date
investigating the biophysical effect of MUC13 expression in these cancers. Based on the
nanoindentation and additional supporting data discussed in this section, we can conclude
that differential MUC13 expression has significant biophysical effects on PanCa cells.
When observing the effect of MUC13 on the biophysical properties in these cells,
PanCa cells gave the initially anticipated result. MUC13 overexpression led to a
significant reduction in the cell modulus (Figure 4-1), which is expected for changes
leading to an increased oncogenicity. HPAF-II cells also showed the anticipated effect
with MUC13 knockdown in the form of significant increases in both modulus and
adhesion (Figure 4-2).
Similar results were also seen in other gastrointestinal cancers. Specifically,
recent results published our lab have shown that, in a similar manner to PanCa cells,
overexpression and knockdown of MUC13 cells in colorectal cancer leads to either an
increase or decrease in various motility-based assays, respectively.19 Curiously,
nanoindentation on these cells indicated an opposite trend than what was seen in PanCa
cells - namely, with overexpression of MUC13 in SW480 cells, an increased modulus
was noted, but with knockdown in SW620 cells, a reduction was seen. The trends seen in
CRC are the opposite of the expected result of this study. Although the effects on cellular
motility were the same, this difference in biophysical changes seems to indicate that the
manner in which MUC13 affects cancer cells is tissue specific. Furthermore, similar
adhesion results were seen in aggregation assays conducted with these CRC modulated
cells. Notably, SW480 MUC13 overexpressing cells had a lower overall aggregation
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Figure 4-4.

Effect of MUC13 modulation on cellular aggregation.

(A) Panc-1 cells show decreased cell-cell adhesion with MUC13 overexpression. (B)
HPAF-II cells show increased cell-cell adhesion with MUC13 knockdown. Cells were
imaged at 20x magnification. Representative groups of cells are highlighted with white
squares and magnified images are detailed on the right of each image to show detailed
effect of MUC13 on cellular aggregation.

59

compared to the vector cell line, whereas SW620 cells had more association with MUC13
knockdown (Appendix B. Figures B-1 through B-3).
Of note, there is a considerable change in the base rigidity of Panc-1 and HPAF-II
after transfection has occurred. Specifically, the average rigidity of Panc-1 raised from
approximately 2kPa to nearly 8kPa after transfection with the vector plasmids. In
addition, HPAF-II dropped from around 14kPa to approximately 10kPa. It is unclear as to
the exact mechanism behind this biophysical change; however, we speculate that the
effects of stable transfection and antibiotic selection have caused considerable change in
the cell which led to significant physical changes as well. Of note, at least one study has
shown that transient transfection with siRNA led to minimal changes in biophysical
properties97, however this may be due to a lack of antibiotic selection pressure on the
cells. (Figure B-4)
As mentioned previously, the trends in the overall and regional analyses are
similar. Regional data examining the nuclear, cytoplasmic, and peripheral regions
individually may provide a clearer insight into some of the effects of MUC13 modulation
on cancer cell phenotypes, especially when looking at changes at the periphery of the
cell. Changes at this region may be more closely related to changes in the motility and
adhesive properties in a two-dimensional culture, but all regions of the cell should need
to be considered for three-dimensional effects, as evident by alterations in aggregation.
MUC13 seems to directly impede the ability of cells to aggregate with one
another in vitro. This may be in part to its ability to impede with the association of
cadherins between cells, impacting cell to cell adhesion and facilitating the dissociation
and invasion of cancer cells from the primary tumor. Similar results previously published
from our lab indicated a similar effect on MUC13 modified ovarian cancer cells;
specifically, a reduced aggregation was seen with MUC13 overexpression as compared to
the vector.18 In addition, our lab has previously published data indicating an interaction
between MUC13 and HER2 in PanCa cells, leading to an upregulation of its downstream
pro-oncogenic pathways. This in turn is implicated in affecting various facets of
oncogenicity, including disruption of integrins at the cell membrane, which can lead to a
reduced interaction with the extracellular matrix.161
Furthermore, previous studies have shown an interaction between MUC13 and
HER2 in PanCa cells. This is of note as HER2 is thought to be activated by MUC13, and
in turn reduce the function of E-cadherin which would lower cell-cell adhesion.18,20,161
This may partially explain why cells with overexpressed MUC13 have been shown to
have enhanced motility, as removing E-cadherin from the surface of the cell frees βcatenin, which could then act as a transcription factor to propagate the EMT cycle.93
As shown from previously published data from our lab, knockdown of MUC13 in
HPAF-II cells is associated with a reduction in clonogenic, invasive, migratory, and
proliferative phenotypes. This supports the notion of reduced aggressiveness with an
increased cellular modulus noted in MUC13 KO cells compared to their vector. By
contrast, the overexpression of MUC13 in Panc-1 has the opposite effect, leading to an
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increase in proliferation and clonogenic potential20 - this helps to support the notion that
MUC13 increases cancer cell aggressiveness and leads to a reduction in cellular rigidity.
Recently, our lab showed that in PanCa cells, MUC13 was associated with an increased
glucose uptake and metabolism via stabilizing the Glut-1 protein, allowing cancer cells to
utilize more glucose for various functions.162
Clinically, MUC13 has been shown to be associated with a poorer prognosis in
PanCa. This was shown in recent research by Khan et al, where tissue samples showed a
positive correlation between later stage disease and increased MUC13 expression. In
addition, MUC13 was more pronounced in cancerous tissue compared to normal
adjacent, and especially concentrated in higher stage (Stage III-IV) or metastatic tissue as
demonstrated in one of our lab's previous reports.31 This effect does not appear to be
limited to gastrointestinal cancers - as shown in our lab's previous work on ovarian
cancer, MUC13 expression led to significant changes in cellular motility.18 We can
therefore hypothesize that based on the results from this study, a significant biophysical
effect would occur, but studies would need to be run to see how MUC13 affects ovarian
cancer cells.
Our results indicate the potential of AFM-based nanoindentation for use as a
clinical tool for cancer assessment. Using only the physical changes observed in tumor
samples, it may one day be possible for pathologists to determine the course of a disease
state by measuring physical changes over time and using these changes as prognostic
indicators of disease progression.
Overall, MUC13 seems to impart significant biophysical changes associated with
a promotion of increased metastatic potential. In this paper, we assessed the biophysical
effects of MUC13 modulation on PanCa cells. These cells were first scanned in their
native configuration to determine their baseline physical characteristics. With MUC13
modulation, significant changes were seen in the biophysical parameters for PanCa cells
(modulus and adhesion) which correlated with previous phenotypic data produced from
our lab. When taken together, these data help to show that MUC13 leads to an increased
metastatic potential, which in turn softens the cell leading to an increase in its overall
motility and reduction in cell-cell adhesion.
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CHAPTER 5.

CONCLUSIONS AND FUTURE RESEARCH

Pancreatic cancer remains one of the deadliest cancers with dismal prognosis
rates. Early detection of this disease may be one of the keys to improving these survival
rates. As discussed in this report, I investigated the use of biophysical analysis as a
method of describing different effects on a panel of pancreatic cancer cells. Overall, I
found that the biophysical changes seen in PDAC cells positively correlate with
phenotypic expressions, namely changes in cell aggregation. This can potentially give
insights into various biochemical pathways, such as effects on cell stemness,
differentiation, EMT, and various other pro-oncogenic systems. A brief summary of the
findings of this report are highlighted in Figure 5-1.
In Chapter 2, we examined a panel of cells in their native configuration including
HPNE as a reference for normal, non-cancerous pancreatic epithelia. The results of this
study clearly showed that the normal cell line (HPNE) had a significantly higher modulus
as compared to all other cancerous cells, and a clear delineation of rigidity and adhesion
between various stages of differentiation. The same trend was observed for membrane
adhesion, but to a lesser extent. More poorly differentiated cells were found to have the
lowest overall rigidity, and generally lower adhesion. This adhesion trend was confirmed
with aggregation results, indicating that nanoindentation results can give an indication to
a cell's biophysical state.
The results shown in Chapter 2 give perhaps the most promising potential use for
the AFM in a clinical sense for PDAC - we hope that these results may one day lead to
the use of biophysical analysis as a facile, alternative assay to staging, diagnosing, or
determining a prognosis for patients with PDAC. Although there are multiple methods
that can be considered for diagnosis or early detection, most of these methods rely on
biochemical means, which can be time-consuming and delay critical diagnostic decisions.
For this biophysical analysis to be conducted, we anticipate that physicians would first
extract patient tumor samples, as well as adjacent normal tissue for comparison. These
could then be rapidly attached to a substrate such as a glass slide and measured on an
AFM shortly after surgical extraction to measure physical parameters of the tissue. These
same sections could then be analyzed biochemically for various markers to confirm the
results of the nanoindentation studies. We propose that in this way, the AFM can provide
a more rapid tool to potentially acquire clinical information about a patient's disease state
based only on physical parameters in the sample.
In Chapter 3, we investigated the effect of several chemotherapeutic agents
(GEM, PTX, and CUR) and their biophysical effects on PDAC cells. Interestingly, the
relatively novel agent CUR was shown to have the greatest overall effect, and GEM had
the lowest. Poorly differentiated cells were seen to have significantly larger biophysical
changes as compared to the more well differentiated cell lines. These results help to
indicate how effective different chemotherapeutics are on differing types of PDAC cell
lines, but our long-term goal is to examine these effects at the tissue level. We anticipate
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Figure 5-1.

Summary of key findings in this study.
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using similar techniques on patient-derived tissue sections in the future, and based on the
intensity of the biophysical change in tissues or cells after treatment we predict that
pathologists could more rapidly determine the therapeutic efficacy or even drug
resistance of a tumor to more rapidly determine a prognosis or it altered therapy is
required for a patient.
In addition, it should be noted that not all drugs cause an increase in the modulus
of a cell. Although the three drugs in this study tended to do so, particularly in the more
poorly differentiated cell lines, there are other agents that have caused significant
reductions in a cellular modulus. One notable example is outlined in the Appendices:
VERU-111, a novel tubulin inhibitor.
In Chapter 4, MUC13 modulated cells were generated and analyzed using various
biophysical studies. It was found that MUC13 overexpression in Panc-1 cells led to a
decrease in both the modulus and adhesion of the cells, and that knockdown in HPAF-II
cells led to the opposite effect, indicating that MUC13 has a significant biophysical
impact on cancer cells. This leads to the observation that MUC13 is associated with
biophysical changes involved in a promotion of increased metastatic potential. A positive
correlation was noted between membrane adhesion data as measured with the AFM
studies and a series of aggregation assays, indicating the ability of the AFM to predict
phenotypic characteristics of the cells with genetic modification. In a similar manner to
what was discussed about the results with therapeutic treatment, it is conceivable that
many other genetic alterations will lead to physical differences. Again, based on the
intensity of this change it may be possible to determine the overall prognosis or staging
of the disease.
Overall, our data indicate that biophysical parameters as measured by atomic
force microscopy can detect the effects of various changes in PDAC cells in vitro. Using
this knowledge, it is our long term goal that this knowledge be used in patient derived
tissue samples, as a facile method of determining cancer grades, therapeutic efficacy, and
potentially even prognosis of the disease state, comparing cancerous tissue to its normal
counterpart or treated tissue over a particular timeframe. We believe that in the proper
setting, this can give a rapid and straightforward analysis to pathologists to more quickly
determine the disease course without having to rely completely on immunohistochemistry
or other biochemical tests.
Such physical changes can potentially be useful to determine various oncogenic
processes, including EMT, metastasis, or maybe even determining how susceptible or
resistant a tumor is to a given therapy. Our data help to prove the predictive power of
biophysical analyses in measuring the effect of various modifications to the cell.
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APPENDIX A. SUPPLEMENTARY MATERIAL MENTIONED IN CHAPTER 3

Figure A-1. Overall analysis of chemotherapeutic treatments on adhesive
properties of PDAC cells.
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Figure A-2. Biophysical effects of VERU-111 (free drug and PLGA
nanoformulations) on Caski cervical cancer cells.
Cells were treated with 10nM of both free VERU and nanoparticle formulation. Cells
were analyzed in the same method described in Chapter 3.
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Figure A-3. Biophysical effects of VERU-111 (free drug and PLGA
nanoformulations) on SiHa cervical cancer cells.
Cells were treated with 10nM of both free VERU and nanoparticle formulation. Cells
were analyzed in the same method described in Chapter 3.
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Figure A-4. Biophysical effects of curcumin-loaded magnetic nanoparticles on
PDAC cells and tissues.
(A and B) Graphs depicting changes in elastic properties of Panc-1 (A) AsPC-1 (B) cells
on treatment with SP-CUR (p < 0.05). (C and D) Representative images and
corresponding graphs comparing elastic modulus (p = 0.0006) (C) and adhesion
properties (p = 0.2385) (D) of FFPE tumor tissues from SP and SP-CUR treated
orthotopic nude mice. P values as p < 0.05 are considered significant and are denoted as *
symbol.
Modified from final submission with permission from Elsevier. Khan S, Setua S, Kumari
S, et al. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine
therapeutic response in pancreatic cancer. Biomaterials. 2019;208:83-97.
doi:10.1016/j.biomaterials.2019.04.005. [125].
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Figure A-5.

Synthesis and characterization of PLGA-PTX nanoparticles (PPNPs).

(A) Schematic overview of PPNPs synthesis. (B) DLS characterization of PLGA and
PPNPs. (C) DLS characterization of zeta potential for PLGA and PPNPs. (D) FTIR
spectra for free PTX, PLGA, and PPNPs. (E) XRD spectra for free PTX, PLGA, and
PPNPs. (F) Topographical and physical analysis of PLGA and PPNPs by atomic force
microscopy (AFM). Representative 2D and 3D images (2 × 2 μm2) of PLGA and PPNPs
(i-ii). Modulus data for two separate samples (iii-iv).
Reprinted from final submission with permission from Elsevier. Massey AE, Sikander
M, Chauhan N, et al. Next-generation paclitaxel-nanoparticle formulation for pancreatic
cancer treatment. Nanomedicine Nanotechnology, Biol Med. 2019;20.
doi:10.1016/j.nano.2019.102027. [127].
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Figure A-6.

Physical characteristics of living cells after treatment with PPNPs.

(A) Analysis of ASPC1 cells. Three-dimensional images of of untreated (i) and PPNPstreated (ii) cells showing morphological changes with treatment (10nM for 24 hours). (iii)
Summary of physical data collected by AFM force analysis showing changes in modulus
and adhesion with PPNP treatment. (B) Analysis of Panc1 cells. Three-dimensional
images of of untreated (i) and PPNPs-treated (ii) cells showing morphological changes
with treatment (10nM for 24 hours). (iii) Summary of physical data collected by AFM
force analysis showing changes in modulus and adhesion with PPNP treatment.
Reprinted from final submission with permission from Elsevier. Massey AE, Sikander
M, Chauhan N, et al. Next-generation paclitaxel-nanoparticle formulation for pancreatic
cancer treatment. Nanomedicine Nanotechnology, Biol Med. 2019;20.
doi:10.1016/j.nano.2019.102027. [127].
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APPENDIX B. SUPPLEMENTARY MATERIAL MENTIONED IN CHAPTER 4

Figure B-1.
cells.

Biophysical effects of MUC13 overexpression on SW480 colorectal

(A) Confirmation of MUC13 expression with PCR analysis. (B) Change in modulus with
MUC13 overexpression. (C) Representative modulus images with MUC13
overexpression. (D) Changes in membrane adhesion with MUC13 overexpression. (E)
Representative images of adhesion with MUC13 overexpression.
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Figure B-2.

Biophysical effects of MUC13 knockdown on SW620 colorectal cells.

(A) Confirmation of MUC13 expression with PCR analysis. (B) Change in modulus with
MUC13 knockdown. (C) Representative modulus images with MUC13 knockdown. (D)
Changes in membrane adhesion with MUC13 knockdown. (E) Representative images of
adhesion with MUC13 knockdown
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Figure B-3. Representative aggregation assay results showing effects of MUC13
modulation on aggregative potential in colorectal cancer cells.
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Figure B-4.

Biophysical effects of cellular transfection on pancreatic cancer cells.
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